0001213900-16-018813.txt : 20161121 0001213900-16-018813.hdr.sgml : 20161121 20161121152955 ACCESSION NUMBER: 0001213900-16-018813 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161121 DATE AS OF CHANGE: 20161121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIFESTYLE MEDICAL NETWORK, INC. CENTRAL INDEX KEY: 0001307140 STANDARD INDUSTRIAL CLASSIFICATION: TELEVISION BROADCASTING STATIONS [4833] IRS NUMBER: 131026995 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-52408 FILM NUMBER: 162010241 BUSINESS ADDRESS: STREET 1: 121 S. ORANGE AVE STREET 2: SUITE 1510 CITY: ORLANDO STATE: FL ZIP: 32801 BUSINESS PHONE: 407-620-1063 MAIL ADDRESS: STREET 1: 121 S. ORANGE AVE STREET 2: SUITE 1510 CITY: ORLANDO STATE: FL ZIP: 32801 FORMER COMPANY: FORMER CONFORMED NAME: EMERGING MEDIA HOLDINGS INC DATE OF NAME CHANGE: 20070104 FORMER COMPANY: FORMER CONFORMED NAME: Beverly Hills Film Studios Inc DATE OF NAME CHANGE: 20041027 10-Q 1 f10q0916_lifestylemedical.htm QUARTERLY REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

☒   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2016

 

☐  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______________ to _______________

 

Commission file number 000-52408

 

LIFESTYLE MEDICAL NETWORK INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   13-1026995
(State or Other Jurisdiction of   (I.R.S. Employer
Incorporation or Organization)    Identification No.)

 

424 E. Central Blvd., Orlando, FL   32801
(Address of principal executive offices)   (Zip Code)

 

(407) 514-1230

(Registrant's Telephone Number, Including Area Code)

 

 

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐  No ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. (Check One):

 

Large accelerated filer  ☐ Accelerated filer  ☐
   
Non-accelerated filer  ☐ Smaller reporting company   ☒

(Do not check if a smaller reporting company)

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒

 

The number of shares outstanding of the issuer's common stock, $0.001 par value per share, was 33,958,257 as of November 18, 2016.

 

 

 

 

 

 

LIFESTYLE MEDICAL NETWORK, INC.

 

INDEX

 

    Page
     
Part I.   Financial Information 1
     
Item 1. Financial Statements. 1
     
  Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015 (unaudited) 2
     
  Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015 (unaudited) 3
     
  Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015 (unaudited) 4
     
  Notes to Unaudited Consolidated Financial Statements 5
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 12
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 15
     
Item 4. Controls and Procedures. 15
     
Part II. Other Information 16
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 16
     
Item 6.   Exhibits. 17
     
Signatures 18

 

 

 

 

PART I — FINANCIAL INFORMATION

 

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS.

 

Certain information and footnote disclosures required under accounting principles generally accepted in the United States of America have been condensed or omitted from the following consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission. The following unaudited consolidated financial statements should be read in conjunction with the year-end restated consolidated financial statements and notes thereto included in the Company's Form 10-K for the year ended December 31, 2015.

 

The results of operations for the three and nine months ended September 30, 2016 and 2015 are not necessarily indicative of the results for the entire fiscal year or for any other period.   

 

 1 

 

 

LIFESTYLE MEDICAL NETWORK INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

   September 30,   December 31, 
   2016   2015 
   (Unaudited)     
ASSETS        
         
CURRENT ASSETS:        
Cash and cash equivalents  $150,869   $49,719 
Accounts receivable-related party   572,850    516,868 
Accounts receivable   5,733    - 
Loan receivable-related party   677,560    100,000 
Prepaid expenses   311,336    53,107 
Total Current Assets   1,718,348    719,694 
           
Property, plant and equipment - net   353,213    134,296 
Other assets   242,525    - 
Intangible assets - net   79,174    83,338 
TOTAL ASSETS  $2,393,260   $937,328 
           
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)          
           
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $266,515   $197,877 
Notes payable   525,000    250,000 
Convertible notes payable,net of $257,055 and $105,935 debt discount   858,465    644,065 
           
Total Current Liabilities   1,649,980    1,091,942 
           
LONG-TERM LIABILITIES:          
Convertible notes payable,net of $7,488 debt discount   42,512    - 
           
Total Liabilities   1,692,492    1,091,942 
           
Commitments and Contingencies   -    - 
           
STOCKHOLDERS' EQUITY (DEFICIENCY):          
Common stock, $.001 par value, 200,000,000 shares  authorized; 33,958,257 and 33,658,257 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively   33,959    33,659 
Additional paid-in-capital   10,194,495    9,172,696 
Accumulated deficit   (9,527,686)   (9,360,969)
Total Stockholders' Equity (Deficiency)   700,768    (154,614)
           
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)  $2,393,260   $937,328 

 

See notes to unaudited consolidated financial statements

 

 2 

 

 

LIFESTYLE MEDICAL NETWORK INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2016   2015   2016   2015 
Revenues:                
Management fees-related party  $367,500   $216,000   $935,250   $379,500 
Management fees   195,339    -    195,339    - 
Rental income-related party   112,500    103,500    326,250    206,983 
Total revenues   675,339    319,500    1,456,839    586,483 
                     
Costs and expenses:                    
Cost of revenue related to management fees   202,613    108,251    507,220    138,035 
Cost of revenue related to rental income   67,894    67,894    203,682    135,914 
Selling, general and administrative expenses   135,509    161,658    465,023    372,810 
Amortization of warrants   (32,611)   58,000    47,389    625,335 
Total Costs and expenses   373,405    395,803    1,223,314    1,272,094 
                     
Income (loss) from operations   301,934    (76,303)   233,525    (685,611)
                     
Other income (expense):                    
Loss on extinguishment of debt   -    -    (61,697)   - 
Other income   -    -    25,000    - 
Interest expense   (161,072)   (32,082)   (363,545)   (64,532)
Total Other income (expense)   (161,072)   (32,082)   (400,242)   (64,532)
                     
Income (loss) from operations before provision for income taxes   140,862    (108,385)   (166,717)   (750,143)
                     
Provision for income taxes   -    -    -    - 
                     
Net income (loss)  $140,862   $(108,385)  $(166,717)  $(750,143)
                     
Income (loss) per common share-basic  $0.00   $(0.00)  $(0.01)  $(0.02)
                     
Income (loss) per common share- diluted  $0.00   $(0.00)  $(0.01)  $(0.02)
                     
Weighted average common shares outstanding - basic   33,958,257    33,506,609    33,775,410    32,849,658 
                     
Weighted average common shares outstanding - diluted   45,441,075    33,506,609    33,775,410    32,849,658 

 

See notes to unaudited consolidated financial statements

 

 3 

 

 

LIFESTYLE MEDICAL NETWORK INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   For The Nine Months Ended 
   September 30, 
   2016   2015 
Cash flows from operating activities:        
Net loss  $(166,717)  $(750,143)
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization of intangible assets   4,164    18,534 
Depreciation   56,083    17,632 
Loss on extinguishment of debt   61,697      
Stock-based compensation   24,000    116,000 
Amortization of debt discount   254,095    625,335 
Changes in operating assets and liabilities:          
Accounts receivable   (61,715)   (310,000)
Prepaid expenses   79,247    (84,150)
Accounts payable and accrued expenses   127,856    20,901 
Net Cash Provided by (used in) Operating Activities   378,710    (345,891)
           
Cash flows from investing activities:          
Refund of deposit   -    100,000 
Advances to related party   (842,560)   (135,000)
Repayments by related party   265,000    80,000 
Purchase of equipment   -    (145,448)
Net Cash Used In Investing Activities   (577,560)   (100,448)
           
Cash flows from financing activities:          
Proceeds from related parties   -    42,351 
Repayment of related party debt   -    (142,351)
Repayment of short-term debt   (30,000)   - 
Proceeds from short-term debt   330,000    600,000 
Net Cash Provided by Financing Activities   300,000    500,000 
           
Net change in cash   101,150    53,661 
           
Cash and cash equivalents - Beginning of period   49,719    163 
           
Cash and cash equivalents - End of period  $150,869   $53,824 
           
Supplementary information:          
           
Cash paid for:          
Interest  $-   $28,750 
           
Income taxes  $-   $- 
           
Non-cash Investing and Financing Activities          
           
Conversion of debt and interest for common stock  $-   $999,180 
           
Equipment purchased with notes payable  $275,000   $- 
           
Issuance of common stock for services  $-   $116,000 
           
Beneficial conversion feature  $418,099   $40,000 
           
Issuance of warrants for prepaid services  $580,000   $- 

 

See notes to unaudited consolidated financial statements

 

 4 

 

 

LIFESTYLE MEDICAL NETWORK INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AS OF AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2016 AND 2015

 

1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The consolidated balance sheet as of September 30, 2016 and the consolidated statements of operations, stockholders' deficiency and cash flows for the periods presented have been prepared by Lifestyle Medical Network, Inc. and Subsidiaries (the "Company" or "Lifestyle") and are unaudited. The consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods, and consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations, changes in stockholders' deficiency and cash flows for all periods presented have been made. The information for the consolidated balance sheet as of December 31, 2015 was derived from audited financial statements of the Company.

 

Organization

 

Lifestyle Medical Network Inc. and Subsidiaries (the “Company” or “Lifestyle”) was incorporated in the State of Nevada.  The Company directs its operations through its subsidiaries.  The Company, through its consulting subsidiaries, plans to continue to identify and enter into management and professional consulting services agreements, and to license medical and health technologies, to medical and health clinic operating companies. The Company also intends to open, operate and acquire medical and health clinics, if financing is available and the profile of the clinics’ is favorable.

 

Material Agreements

 

The Company entered management agreements, and have commenced recognizing revenues thereunder, with two medical professional associations located in Houston, Texas, MED-Cure Primary Care Physicians, P.A. and MED-CURE Anti-Aging and Skin Care, P.A. (the “MED-CURE Companies”), effective April 1, 2015, which were purchased by Dr. Ronald Moomaw, a director of the Company. The MED-CURE Companies between them operate six medical clinics in Houston, of which four are primary care clinics and two are skin care clinics. Under management agreements with the MED-CURE Companies, the Company, through its subsidiary LifeStyle Texas Medical Management, LLC (“LifeStyle Management”), provides organizational development, accounting, human resources, computer technical support compliance, scheduling, marketing and advertising, office space, equipment supplies and other management services and receives an agreed percentage of the gross revenues of the practice group, with adjustments designed to ensure that management fees do not exceed an agreed cap, or that the monthly payments do not result in an event of default under the acquisition financing documents for the MED-CURE Companies. The leasing arrangements for the properties leased for the MED-CURE Companies’ clinics’ offices were restructured, with our real estate subsidiary, LifeStyle Texas Real Estate. LLC leasing the properties and then subleasing the properties back to the MED-CURE Companies.

 

Through our subsidiary, Regional Professional Alliance, Inc. , a physician’s professional consulting company that provides professional medical consulting services to medical management companies related to matters affecting professional licensure and medical clinic compliance matters for the benefit of clinics managed by Lifestyle Management, we have entered into an agreement with Dr. Moomaw to provide services through Regional Professional Alliance for the benefit of LifeStyle Management related to oversight and professional medical services coordination of the managed clinics which have entered into management services agreements with LifeStyle Management. Through LifeStyle Texas Licensing, LLC (“LifeStyle Licensing”), the Company plans to sublicense to the MED-CURE Companies the non-exclusive right to use, and to sublicense the use of, certain patents, trademarks, trade names, logos, slogans, trade dress, commercial symbols, operational systems, and other intellectual property rights, in connection with operating and managing medical clinics that provide medical services and/or products of a character and quality, in particular relating to men’s health and weight management.

 

Going Concern

 

The consolidated financial statements for the period ended September 30, 2016 have been prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has a past history of recurring losses from operations and is a development stage company. The Company will require additional funding to execute its future strategic business plan. Successful business operations and its transition to attaining profitability are dependent upon obtaining additional financing and achieving a level of revenue to support its cost structure. These factors raise substantial doubt about the Company's ability to continue as a going concern.

 

 5 

 

 

The Company has entered into Management agreements with six medical clinics in Houston, Texas. The Company will provide services to the clinic and will receive an agreed percentage of gross revenues of the practice group. Management intends to make further acquisitions of other medical clinics during 2016.

 

Management believes these acquisitions will be profitable and the cash flows from these operations will enable the Company to fund the operations of the consolidated group over the next twelve months. Therefore, the annual financial statements continue to be prepared on a going concern basis.

 

Significant Accounting Policies

 

The Company’s significant accounting policies are summarized in Note 1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. There were no significant changes to these accounting policies during the nine months ended September 30, 2016 and the Company does not expect that the adoption of other recent accounting pronouncements will have a material impact on its financial statements.

 

2.INTANGIBLES

 

The MPL License Agreement

 

The MPL License Agreement, under which the Company's wholly-owned subsidiary, Elite, is the licensee pursuant to the Assignment from WMA, provides for the license of medical services, operational systems, manuals, certain names and logo designs and other intellectual property in connection with the operation of medical clinics that provide services related to men’s health within the territory of the continental United States (the “Licensed Rights”). The License Agreement provides for a fee of 6% of gross receipts of Licensee, payable quarterly. The term of the License Agreement is for twenty (20) years from the effective date, May 9, 2011. The Company plans to establish new medical clinics or acquire existing clinics, as well as to provide consulting services to medical clinics utilizing the Licensed Rights.

 

Intangibles are the value of the MPL license. Amounts assigned to this intangible were determined by management. Management considered a number of factors in determining the allocations, including valuations and independent appraisals. The intangibles are being amortized over 19.5 years, the life of the license.

 

The components of intangible assets are as follows:

 

  License Agreements
       
  Balance January 1, 2015  $88,893 
        
  Amortization for the year ended December 31, 2015   (5,555)
        
  Balance December 31, 2015   83,338 
        
  Amortization for the nine months ended September 30, 2016   (4,164)
        
  Balance September 30, 2016  $79,174 

 

Amortization expense for the nine months ended September 30, 2016 and 2015 amounted to $4,164 and $4,165, respectively.

 

 6 

 

 

Estimated amortization expense for intangible assets for the next five years is as follows:

 

  Year Ending  Amortization 
  December 31,  Expense 
  2016   1,391 
  2017   5,555 
  2018   5,555 
  2019   5,555 
  2020   5,555 

 

3.LOAN RECEIVABLE-RELATED PARTY

 

The Company advanced operating funds on a short-term basis to the MedCure Companies during the year ended December 31, 2015. The Company advanced the MedCure Companies $180,000 and received repayments of $80,000. During the nine months ended September 30, 2016, the Company advanced an additional $842,560 and received repayments of $265,000. As of September 30, 2016 and December 31, 2015, the MedCure Companies owed the Company $677,560 and $100,000, respectively.

 

4 PROPERTY AND EQUIPMENT

 

Property and equipment consists of the following:

 

     September 30,   December 31, 
     2016   2015 
  Equipment  $432,152   $157,152 
  Accumulated depreciation   78,939    22,856 
     $353,213   $134,296 

 

Depreciation expense for the nine months ended September 30, 2016 and 2015 was $56,083 and $16,632, respectively.

 

 7 

 

 

5. DEBT

 

Short-term debt as of September 30, 2016 and December 31, 2015 were as follows:

 

     September 30,   December 31, 
     2016   2015 
  Short-term Debt        
           
  Secured promissory note, interest @ 12% per annum, due June 30, 2016  $150,000   $150,000 
             
  Unsecured promissory note, interest @ 10%, due June 30, 2016   75,000    75,000 
             
  Convertible promissory note, interest @ 10% per annum, due April 2, 2016   100,000    100,000 
             
  Convertible promissory note, interest @ 12% per annum, due April 28, 2017 and June 8, 2017 (2)   358,465    431,465 
             
  Convertible promissory note, interest @ 12% per annum, due December 17, 2016   100,000    100,000 
             
  Convertible promissory note, interest @ 10% per annum, due September 23, 2016   50,000    12,600 
             
  Unsecured promissory note, interest @ 10% per annum, due November 1, 2016   25,000    25,000 
             
  Secured promissory note, interest @ 6% per annum due April 1, 2017 (4)   275,000    - 
             
  Convertible promissory note, interest @ 12% per annum, due June 13, 2017 (3)   250,000    - 
             
  Convertible promissory note, interest @ 12% per annum, due August 24, 2018 (5)   42,512    - 
      1,425,977    894,065 
  Less: Current portion   1,383,465    894,065 
  Long-term debt  $42,512   $- 

 

(1)On February 18, 2016, the Company executed an unsecured promissory note with Gail Keats and received $30,000. The promissory note is interest-free and is payable on or before August 15, 2016. The Company repaid the note in full in July 2016.

 

(2)On May 16, 2016, the Company amended its loan agreements with Roy Meadows (“Meadows”). The Company agreed to pay Meadows a renewal fee of $28,000 and $27,956 on its two outstanding loans with Meadows and extend the maturity dates of the loans to April 28, 2017 and June 8, 2017, respectively. The new outstanding balances of the loans including interest and the renewal fees amounted to $308,000 and $307,520, respectively.

 

The Company also agreed to amend the conversion price of the loans into the Company’s common stock to $0.10 per share. At any time, the holder of the notes, at his option, shall have the right to convert the outstanding principal balance or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company. The fair value of the common stock at the date of issuance of the advance was $0.13, which created a Beneficial Conversion Feature of $409,766, the Beneficial Conversion Feature was recorded as a debt discount over the life of the notes. The debt discount as of September 30, 2016 was $257,055.

 

 8 

 

 

The Company performed an analysis under ASC 470-50 criteria to determine if the note extension agreement falls under debt modification or debt extinguishment criteria. The Company revalued the warrants issued and agreed the additional consideration, extended maturity dates and interest to the extended agreement. The Company deems that based on the analysis performed, debt extinguishment does exist and recorded loss on debt extinguishment in the amount of $61,697.

 

(3)On June 13, 2016, the Company issued a convertible promissory note to Meadows and received proceeds of $250,000.The promissory note bears interest @ 12% per annum and matures one year from the date of issuance. On October 13, 2016, the promissory note was amended increasing the principal amount to $500,000 under the same terms and conditions of the promissory note for funds received in a second loan advance. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.15 per share.

 

(4)On April 1, 2016, the Company issued a secured promissory note to Emile Fares, M,D, (the “Payee”) and promised to the Payee $275,000 in exchange for all the medical equipment owned by RMC Totalcare Medical PA.. The secured promissory note bears interest @ 6% per annum and matures one year from the date issuance. A payment of $75,000 is due October 1, 2016 and the balance due on the maturity date. The note is secured by all collections received by LifeStyle Texas Medical Management LLC pursuant to a Management Agreement with RMC Totoalcare Medical PA.

 

(5)On August 24, 2016, the Company issued a convertible note to Daniel Hagen and received proceeds of $50,000. The promissory note bears interest @ 10% per annum and matures on August 24, 2018. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.06 per share. The fair value of the common stock at the date of issuance of the advance was $0.07, which created a Beneficial Conversion Feature of $8,333, the Beneficial Conversion Feature was recorded as a debt discount over the life of the note. The debt discount as of September 30, 2016 was $7,488.

 

Interest expense for the nine months ended September 30, 2016 and 2015 amounted to $107,484 and $64,532, respectively.

 

6.ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

     September 30,   December 31, 
     2016   2015 
  Interest  $118,477   $68,807 
  Salaries - Officer   -    1,125 
  Professional fees   98,221    64,306 
  Consulting   33,515    48,000 
  Other   16,302    15,639 
     $266,515   $197,877 

 

7. BASIC AND DILUTED EARNINGS PER SHARE

 

Basic earnings per share are computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share are computed by dividing net earnings by the weighted-average number of common shares and dilutive potential common shares outstanding during the period. At September 30, 2016, there were 11,622,521 potential common shares. Because of the net loss, the effect of these potential common shares is anti-dilutive.

 

8.WARRANTS

 

During September 2016, the Company issued warrants to four consultants to purchase 6,500,000 shares of the Company’s common stock at exercise prices of $0.07 and $0.08 per share. The warrants were issued in connection with services to be provided to the Company over the next two years. The fair value of the warrants were $500,000, of which $7,499 was expensed during the nine months ended September 30, 2016 and the balance of $492,501 is included in Prepaid expenses as of September 30, 2016.

 

 9 

 

 

On April 1, 2016, the Company issued a warrant to Harcharan Narang M.D, to purchase 800,000 shares of the Company’s common stock at an exercise price of $0.20 per share. The warrant was issued in connection with services provided to the Company. The fair value of the warrant was $80,000, of which $39,890 was expensed during the nine months ended September 30, 2016 and the balance of $40,110 is included in prepaid expenses at September 30, 2016.

 

On May 16, 2016, the Company issued a warrant to Roy Meadows to purchase 1,059,564 shares of the Company’s common stock at an exercise price of $0.025 per share. The purchase warrant consist of a bonus warrant of 500,000 shares and a renewal warrant of 559,564 shares issued in connection with the extension of two Meadows’ notes. The fair value of the warrants amounted to $112,555. This amount has been included with the debt discount against the Roy Meadows noteand will be amortized over the life of the note.

 

On June 13, 2016, the Company issued a warrant to Roy Meadows to purchase 250,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The warrant was issued in connection with a financing provided to the Company. The fair value of the warrant was $17,500, of which $5,104 was expensed during the nine months ended September 30, 2016.

 

The estimated value of the warrants was determined using the Black Scholes pricing model using the following assumptions: expected term of 5 to 7 years, a risk free interest rate between 1.39% and 1.56%, a dividend yield of -0- and volatility between 202% and 424%. The fair value of the warrants amounted to $708,910.

  

The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company's common stock issued to non-employees of the Company. The warrants were granted in lieu of cash compensation for services performed.

 

         Exercise   Remaining  Intrinsic 
     Shares   Price   Life  Value 
  Outstanding, January 1, 2016   8,000,000   $0.13   4.6     
  Granted   8,609,564    0.08   5.0     
  Expired/Cancelled   -    -         
  Exercised   -    -         
  Outstanding-period ending September 30, 2016   16,609,564   $0.12   4.8 years  $81,430 
  Exercisable-period ending September 30, 2016   16,609,564   $0.12   4.8 years  $81,430 

 

9.RELATED PARTY TRANSACTIONS

 

a) Dr. Ronald Moomaw (“Moomaw”), a director of the Company, is the sole owner of the MED-CURE Companies. The Company received a majority of its revenue for the nine months ended September 30, 2016 from the MED-Cure Companies.

 

In connection with the management of the Med-Cure Companies, Moomaw was issued a warrant for the purchase of 5,000,000 shares of the Company?s common stock valued @ $465,000, the fair value at the time of issuance, April 17, 2015.  

 

Moomaw also received consulting fees of $114,800 and $39,600 for the nine months ended September 30, 2016 and 2015, respectively, as part of his management compensation.  

 

b) The Company advanced operating funds on a short-term basis to the MED-CURE Companies and received payments during the nine months ended September 30, 2016 and the year ended December 31, 2015. As of September 30, 2016 and December 31, 2015, the MED-CURE Companies owe the Company $677,560 and $100,000, respectively.

 

10. COMMON STOCK

 

On June 15, 2016, the Company issued 100,000 shares of the Company’s common stock to LKB Partners LLC in connection with a service agreement with the Company. The fair value of the common stock issued was $8,000, of which $6,000 was expensed during the nine months ended September 30, 2016.

 

On June 15, 2016, the Company issued 200,000 shares of the Company’s common stock to Harcharan Narang M.D. in connection with a service agreement with the Company. The fair value of the common stock issued was $16,000, all of which was expensed during the nine months ended September 30, 2016.

 

 10 

 

 

11.MAJOR CUSTOMERS

 

87% of the revenues for the nine months ended September 30, 2016, was received from companies owned 100% by Dr. Ronald Moomaw, a director of the Company.

 

12.COMMITMENTS AND CONTINGENCIES

 

Consulting Agreements

 

a)During 2015 and 2014, Lifestyle entered into various consulting agreements with third parties in connection with business advisory services. For the nine months ended September 30, 2016 and 2015, consulting services amounted to $190,579 and $111,187, respectively.

 

b)On July 1, 2012, Lifestyle entered into an employment agreement with Christopher Smith("Smith"), the Company's Chief Executive Officer. The term of the agreement is for five years. Effective August 1, 2015, the monthly salary for Smith was increased to $12,500. Smith will also receive a performance bonus based on a percentage of the Company's net operating profit before income taxes. For the nine months ended September 30, 2016, and 2015, payroll-officer amounted to $112,500 and $60,000, respectively.

 

 11 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and notes thereto and the other financial information included elsewhere in this report.  Certain statements contained in this report, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements involve known and unknown risks and uncertainties.  Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including our ability to create, sustain, manage or forecast our growth; our ability to attract and retain key personnel; changes in our business strategy or development plans; competition; business disruptions; adverse publicity; and international, national and local general economic and market conditions.

 

Organization

 

The Company was incorporated in the State of Nevada on September 3, 2003, under the name Beverly Hills Film Studios, Inc. and changed its name to Emerging Media Holdings, Inc. on September 28, 2006. On September 30, 2006, we acquired IM “Media Alianta” SRL, the 100% owner of SA “Analiticmedia-Grup”, both Moldovan companies ("AMG"), and on May 2, 2008 “TNT-Bravo” channel-ICS “Media Top Prim” SRL, the exclusive operator in Moldova of Russian channel TNT programs owned by Gazprom Media.

 

We changed the focus of our business and disposed of three of our Moldova media subsidiaries on February 10, 2011. On December 29, 2011, we completed the sale of our remaining Moldova media subsidiaries and acquired rights to technologies and practices pursuant to an October 5, 2010 License Agreement for operating technologies and processes services related to men’s health within the territory of the continental United States. On February 2, 2012, we acquired the full assignment of rights to this License Agreement. Effective July 31, 2012, the name of our Company was changed from Emerging Media Holdings, Inc. to Lifestyle Medical Network Inc.  

 

Recent Developments

 

Dr. Ronald Moomaw, a director of the Company and a licensed physician in the State of Texas, who had been assisting the Company in evaluating the acquisition by the Company of two medical practices in Houston, Texas, purchased the two medical professional associations (the “MED-CURE Companies”), effective April 1, 2015, for a purchase price of $2,500,000, utilizing local bank financing. The MED-CURE Companies between them operate six medical clinics in Houston, of which four are primary care clinics and two are skin care clinics. The MED-CURE Companies agreed, effective April 1, 2015, to enter into management agreements with the Company, pursuant to which the Company, through its subsidiary Lifestyle Texas Medical Management, LLC (“Lifestyle Management”), has provided organizational development, accounting, human resources, computer technical support compliance, scheduling, marketing and advertising, office space, equipment supplies and other management services and receives an agreed percentage of the gross revenues of the practice group, with adjustments designed to ensure that management fees do not exceed an agreed cap, or that monthly payments do not result in an event of default under the acquisition financing documents for the MED-CURE Companies. The leasing arrangements for the properties leased for the MED-CURE Companies’ clinics’ offices were restructured, with our real estate subsidiary, Lifestyle Texas Real Estate, LLC, leasing the properties and then subleasing the properties back to the Med-Cure Companies.

 

 12 

 

 

Dr. Moomaw on April 21, 2016, acquired an additional clinic in Houston, Texas, which clinic is now operated under the name RCM Total Care Medical PA, PLLC. The Total Care Clinic is managed by Lifestyle Management, pursuant to management agreements between the Lifestyle Management and the clinics for the provision of administrative and business services by the Management Company for the physician practices of the clinics. The clinics will enter into license agreements with Lifestyle Licensing, for the license of specified protocols and procedures for application in their respective medical practices.

 

Through our subsidiary, Regional Professional Alliance, Inc., a physician’s professional consulting company that provides professional medical consulting services to medical management companies related to matters affecting professional licensure and medical clinic compliance matters for the benefit of clinics managed by Lifestyle Management, we have entered into an agreement with Dr. Moomaw to provide services through Regional Professional Alliance for the benefit of Lifestyle Management related to oversight and professional medical services coordination of the managed clinics which have entered into management services agreements with Lifestyle Management. Through Lifestyle Texas Licensing, LLC (“Lifestyle Licensing”), the Company plans to sublicense to the MED-CURE Companies and RCM Total Care the non-exclusive right to use, and to sublicense the use of, certain patents, trademarks, trade names, service marks, logos, slogans, trade dress, commercial symbols, operational systems, and other intellectual property rights, in connection with operating and managing medical clinics that provide medical services and/or products of a distinctive character and quality, in particular relating to men’s health and weight management.

 

Throughout this Form 10-Q, the terms "we," "us," "our," "LMN" and the "Company" refer to Lifestyle Medical Network Inc., a Nevada corporation, and unless the context indicates otherwise, includes our subsidiaries.

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our plan of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect our reported results of operations and the amount of reported assets and liabilities.

 

Some accounting policies involve judgments and uncertainties to such an extent that there is reasonable likelihood that materially different amounts could have been reported under different conditions, or if different assumptions had been used. Actual results may differ from the estimates and assumptions used in the preparation of our consolidated financial statements.

 

The Company’s significant accounting policies are summarized in Note 1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.  There were no significant changes to these accounting policies during the nine months ended September 30, 2016, and the Company does not expect that the adoption of other recent accounting pronouncements will have a material impact on its financial statements.

 

PLAN OF OPERATION

 

Through our consulting subsidiaries, we plan to contract to provide management, marketing and professional consulting services, and to license medical and health technologies, to medical and health clinic operating companies. We are evaluating opening and operating a MSO in the near future, assuming the business outlook would be favorable. We also intend to open, operate and acquire men’s medical and health clinics, if financing is available and the profile of the clinics’ services is consistent with the types of medical businesses we view as favorable for acquisition.

 

 13 

 

 

RESULTS OF OPERATIONS

THREE MONTHS ENDED SEPTEMBER 30, 2016 COMPARED TO THE THREE MONTHS ENDED SEPTEMBER 30, 2015

 

During the three months ended September 30, 2016, we had revenues of $675,339, as compared with revenues of $319,500 in the three months ended September 30, 2015, and we recorded a net profit of $140,882 in 2016, as compared with a net loss of $108,385 for 2015. The net profit in 2016 was principally due to an increase in revenues during 2016 offset by an increase in interest expense in 2016. In 2016, cost of revenue related to management fees was $202,613 and of cost of revenue related to rental income was $67,894, for which the 2015 amounts were $108,251and $67,894, respectively, and amortization of warrant expense in 2016 was $32,616, compared to $58,000 in 2015. Interest expense incurred in 2016 was $161,072 and general and administrative expense was $135,509, as compared with interest expense of $32,082 and $161,588 in general and administrative expense in 2015. The increase in cost of revenue in 2016 was due to commencement of medical consulting operations in Houston in April 2015.

 

NINE MONTHS ENDED SEPTEMBER 30, 2016 COMPARED TO THE NINE MONTHS ENDED SEPTEMBER 30, 2015

 

During the nine months ended September 30, 2016, we had revenues of $1,456,839, as compared with revenues of $586,483 in the nine months ended September 30, 2015, and we incurred a net loss of $166,767 in 2016, as compared with a net loss of $750,413 for 2015. The higher net loss in 2015 was principally due to an increase in revenues during 2016 offset by an increase in interest expenses in 2016. Total costs remain constant as increase in operating costs in 2016 were offset by a decrease in the amortization of warrants in 2016. In 2016, cost of revenue related to management fees was $507,220 and of cost of revenue related to rental income was $203,682, for which the 2015 amounts were $138,035 and $135,914, respectively, and amortization of warrant expense in 2016 was $47,389 compared to $625,335 in 2015. Interest expense incurred in 2016 was $363,545 and general and administrative expense was $465,023, as compared with interest expense of $64,532 and $ 372,810 in general and administrative expense in 2015. The increase in cost of revenue and general and administrative expense in 2016 was due to commencement of medical consulting operations in Houston in April 2015.

 

LIQUIDITY AND FINANCIAL RESOURCES

 

At October 31, 2016, we had total assets of $2,393,260 compared to total assets of $937,328 at December 31, 2015. Net cash provided by operating activities in the nine months ended October 31, 2016 was $378,710, as compared with net cash used in operating activities of $345,891 in 2015; net cash used in investing activities was $577,560 in 2016 and $100,448 in 2015; and net cash generated from financing activities was $300,000 in 2016 and $500,000 in 2015.  

 

At October 31, 2016, we had working capital of $68,368. At October 31, 2016, we had total assets of $2,393,260, including cash of $150,869. In 2016 we had revenues of $1,456,839, and incurred a net loss of $166,717. There is no assurance that we will operate profitably in the future.

 

The Company has financed its operations in 2016 in part with issuances of convertible debt to private investors.

 

On February 18, 2016, the Company executed an unsecured promissory note with Gail Keats and received $30,000. The promissory note bears interest at 10% per annum and both principal and interest are payable on or before August 15, 2016. The Company repaid the note in full in July 2016.

 

On April 1, 2016, the Company issued a secured promissory note to Emile Fares, M,D, (the “Payee”) and promised to the Payee $275,000 in exchange for all the medical equipment owned by RMC Totalcare Medical PA.. The secured promissory note bears interest at 6% per annum and matures one year from the date issuance. A payment of $75,000 is due October 1, 2016 and the balance due on the maturity date. The note is secured by all collections received by Lifestyle Texas Medical Management LLC pursuant to a Management Agreement with RMC Totalcare Medical PA.

 

On May 16, 2016, the Company amended its loan agreements with Roy Meadows (“Meadows”). The Company agreed to pay Meadows a renewal fee of $28,000 and $27,956 on its two outstanding loans with Meadows and extend the maturity dates of the loans to April 28, 2017 and June 8, 2017, respectively. The new outstanding balances of the loans including interest and the renewal fees amounted to $308,000 and $307,520, respectively.

 

The Company also agreed to amend the conversion price of the loans into the Company’s common stock to $0.10 per share. At any time, the holder of the notes, at his option, shall have the right to convert the outstanding principal balance or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company. The fair value of the common stock at the date of issuance of the advance was $0.13, which created a beneficial conversion feature of $409,766. The beneficial conversion feature was recorded as a debt discount over the life of the notes. The debt discount as of September 30, 2016 was $257,056.

 

 14 

 

 

On June 13, 2016, the Company issued a convertible promissory note to Meadows and received proceeds of $250,000. The promissory note bears interest at 12% per annum and matures one year from the date of issuance. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.15 per share. 

 

On August 24, 2016, the Company borrowed $50,000 from Daniel Hagen. The loan is at an interest rate of 8%, is due August 24, 2018, and is convertible into common stock at an exercise price of $.06 per share. The fair value of the Company’s common stock on the date of funding of the loan resulted in a beneficial conversion feature of $8,333, which was recorded as a debt discount over the life of the loan. The debt discount as of September 30,2016 was $7,488.

 

There is no assurance that we will be able to obtain sufficient capital to implement our business plans. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  These conditions and uncertainties raise substantial doubt about the Company's ability to continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

  

Off Balance Sheet Arrangements

 

We do not currently have any off balance sheet arrangements falling within the definition of Item 303(c) of Regulation S-B.

 

Inflation

 

To date inflation has not had a material impact on our operations.

 

ITEM 3.  Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

ITEM 4.  Controls and Procedures.

 

As of September 30, 2016, the end of the period covered by this quarterly report, the Chief Executive and Chief Financial Officer of the Company (the “Certifying Officer”) conducted an evaluation of the Company’s disclosure controls and procedures.  As defined under Sections 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the term “disclosure controls and procedures” means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including the Certifying Officer, to allow timely decisions regarding required disclosure.

 

Based on this evaluation, the Certifying Officer has concluded that the Company’s disclosure controls and procedures were not effective for the quarter ended September 30, 2016, to ensure that material information is recorded, processed, summarized and reported by management of the Company on a timely basis to comply with the Company’s disclosure obligations under the Exchange Act, and the rules and regulations promulgated there under.

 

Further, there were no changes in the Company’s internal control over financial reporting during the third fiscal quarter of our 2016 fiscal year that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 15 

 

 

PART II

 

Other Information

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

The following table sets forth the sales of unregistered securities since the Company’s last report filed under this item.

 

Date     Title and Amount(1)   Purchaser   Principal
Underwriter		   Total Offering Price/
Underwriting Discounts
August 24,2016     8% loan in the principal amount of $50,000, due August 24, 2018, convertible into common stock at an exercise price of $.06 per share.   Private Investor.   NA   $ 50,000/NA
September 16, 2016     Five-year common stock purchase warrant, expiring October 1, 2021, to purchase 2,000,000 shares of common stock of the Company, at an exercise price of $.08 per share.   Marketing consultant.   NA   $ -0-/NA
September 16, 2016     Five-year common stock purchase warrant, expiring October 1, 2021, to purchase 2,000,000 shares of common stock of the Company, at an exercise price of $.08 per share.   Marketing consultant.   NA   $ -0-/NA
September 16, 2016     Five-year common stock purchase warrant, expiring October 1, 2021, to purchase 500,000 shares of common stock of the Company, at an exercise price of $.08 per share.   Marketing consultant.   NA   $ -0-/NA
September 30, 2016     Five-year common stock purchase warrant, expiring October 15, 2021, to purchase 2,000,000 shares of common stock of the Company, at an exercise price of $.08 per share.   Marketing consultant.   NA   $ -0-/NA

 

 16 

 

 

(1)The Company believes that the issuance of the warrants and the convertible loan above are transactions exempt from registration as provided by Section 4(a)(2) and Rule 506 of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”). The sale of the convertible loan did not involve a public offering and was made without general solicitation or general advertising to a holder who qualifies as an “accredited investor” under Rule 501 under the Securities Act. Each of the holders acquired the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof. Neither the warrants or convertible loan, nor the underlying shares of common stock issuable upon the exercise or conversion thereof have been registered under the Securities Act and none may be offered or sold in the United States absent registration under the Securities Act or an exemption from such registration requirements.

 

Item 6. Exhibits.

 

31   Certification of Chief Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a)
     
32   Certification of Chief Executive Officer and Principal Financial Officer  pursuant to 18 U.S.C. Section 1350

  

Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.

 

SEC Ref. No.   Title of Document
101.INS   XBRL Instance Document
101.SCH   XBRL Taxonomy Extension Schema Document
101.CAL   XBRL Taxonomy Calculation Linkbase Document
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   XBRL Taxonomy Label Linkbase Document
101.PRE   XBRL Taxonomy Presentation Linkbase Document

 

The XBRL related information in Exhibits 101 to this Quarterly Report on Form 10-Q shall not be deemed “filed” or a part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, and is not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of those sections.

  

 17 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  LIFESTYLE MEDICAL NETWORK INC. 
(Registrant)  
     
Date:   November 21, 2016 By: /s/ Christopher Smith
   

Christopher Smith,
Chief Executive Officer and

Principal Financial Officer

 

 

18

 

 EX-31 2 f10q0916ex31_lifestyle.htm CERTIFICATION

Exhibit 31

 

CERTIFICATION

 

I, Christopher Smith, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Lifestyle Medical Network Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

 

  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date:    November 21, 2016 /s/ Christopher Smith
  Christopher Smith
 

Chief Executive Officer and

Principal Financial Officer

EX-32 3 f10q0916ex32_lifestyle.htm CERTIFICATION

Exhibit 32

 

CERTIFICATION PURSUANT TO

18 U.S.C.  SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Lifestyle Medical Network Inc. (the "Company") on Form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Christopher Smith, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C.  Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

   /s/ Christopher Smith
  Christopher Smith
 

Chief Executive Officer and

Principal Financial Officer
November 21, 2016  

EX-101.INS 4 lmnk-20160930.xml XBRL INSTANCE FILE 0001307140 lmnk:EmploymentAgreementMember 2012-06-29 2012-07-01 0001307140 2014-12-31 0001307140 us-gaap:LicenseAgreementTermsMember 2014-12-31 0001307140 2015-07-01 2015-09-30 0001307140 2015-01-01 2015-09-30 0001307140 lmnk:EmploymentAgreementMember 2015-01-01 2015-09-30 0001307140 lmnk:MedCureCompaniesMember 2015-01-01 2015-09-30 0001307140 lmnk:ConsultingAgreementsMember lmnk:RelatedPartyConsultingServicesMember 2015-01-01 2015-09-30 0001307140 2015-09-30 0001307140 2015-01-01 2015-12-31 0001307140 2015-12-31 0001307140 us-gaap:LicenseAgreementTermsMember 2015-12-31 0001307140 lmnk:UnsecuredPromissoryNoteMember 2015-12-31 0001307140 lmnk:SecuredPromissoryNoteMember 2015-12-31 0001307140 lmnk:UnsecuredPromissoryNoteOneMember 2015-12-31 0001307140 lmnk:ConvertiblePromissoryNoteMember 2015-12-31 0001307140 lmnk:ConvertiblePromissoryNoteOneMember 2015-12-31 0001307140 lmnk:ConvertiblePromissoryNoteTwoMember 2015-12-31 0001307140 lmnk:ConvertiblePromissoryNoteThreeMember 2015-12-31 0001307140 us-gaap:WarrantMember 2015-12-31 0001307140 lmnk:SecuredPromissoryNoteOneMember 2015-12-31 0001307140 lmnk:ConvertiblePromissoryNoteFourMember 2015-12-31 0001307140 lmnk:ConvertiblePromissoryNoteFiveMember 2015-12-31 0001307140 lmnk:UnsecuredPromissoryNoteTwoMember 2016-02-16 2016-02-18 0001307140 lmnk:SecuredPromissoryNoteOneMember 2016-04-01 0001307140 us-gaap:WarrantMember lmnk:HarcharanNarangMDMember 2016-04-01 0001307140 lmnk:SecuredPromissoryNoteOneMember 2016-03-28 2016-04-01 0001307140 us-gaap:WarrantMember lmnk:HarcharanNarangMDMember 2016-03-28 2016-04-01 0001307140 lmnk:ConvertiblePromissoryNoteOneMember lmnk:RoyMeadowsLoanAgreementMember 2016-05-16 0001307140 lmnk:ConvertiblePromissoryNoteOneMember lmnk:OutstandingLoanOneMember lmnk:RoyMeadowsLoanAgreementMember 2016-05-16 0001307140 lmnk:ConvertiblePromissoryNoteOneMember lmnk:OutstandingLoanTwoMember lmnk:RoyMeadowsLoanAgreementMember 2016-05-16 0001307140 us-gaap:WarrantMember lmnk:RoyMeadowsLoanAgreementMember 2016-05-16 0001307140 lmnk:ConvertiblePromissoryNoteOneMember lmnk:RoyMeadowsLoanAgreementMember 2016-05-15 2016-05-16 0001307140 lmnk:ConvertiblePromissoryNoteOneMember lmnk:OutstandingLoanOneMember lmnk:RoyMeadowsLoanAgreementMember 2016-05-15 2016-05-16 0001307140 us-gaap:WarrantMember lmnk:RoyMeadowsLoanAgreementMember 2016-05-15 2016-05-16 0001307140 lmnk:ConvertiblePromissoryNoteSixMember lmnk:OutstandingLoanTwoMember lmnk:RoyMeadowsLoanAgreementMember 2016-05-15 2016-05-16 0001307140 lmnk:ConvertiblePromissoryNoteFourMember lmnk:RoyMeadowsLoanAgreementMember 2016-06-13 0001307140 us-gaap:WarrantMember lmnk:RoyMeadowsLoanAgreementMember us-gaap:SecuritiesFinancingTransactionFairValueMember 2016-06-13 0001307140 lmnk:ConvertiblePromissoryNoteFourMember lmnk:RoyMeadowsLoanAgreementMember 2016-06-11 2016-06-13 0001307140 lmnk:LkbPartnersLlcMember 2016-06-01 2016-06-15 0001307140 lmnk:HarcharanNarangMDMember 2016-06-01 2016-06-15 0001307140 lmnk:ConvertiblePromissoryNoteFiveMember lmnk:DanielHagenMember 2016-08-24 0001307140 lmnk:ConvertiblePromissoryNoteFiveMember lmnk:DanielHagenMember 2016-08-20 2016-08-24 0001307140 2016-07-01 2016-09-30 0001307140 2016-01-01 2016-09-30 0001307140 lmnk:EmploymentAgreementMember 2016-01-01 2016-09-30 0001307140 lmnk:MedCureCompaniesMember 2016-01-01 2016-09-30 0001307140 lmnk:ConsultingAgreementsMember lmnk:RelatedPartyConsultingServicesMember 2016-01-01 2016-09-30 0001307140 lmnk:UnsecuredPromissoryNoteMember 2016-01-01 2016-09-30 0001307140 lmnk:SecuredPromissoryNoteMember 2016-01-01 2016-09-30 0001307140 lmnk:UnsecuredPromissoryNoteOneMember 2016-01-01 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteMember 2016-01-01 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteOneMember 2016-01-01 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteTwoMember 2016-01-01 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteThreeMember 2016-01-01 2016-09-30 0001307140 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteFourMember 2016-01-01 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteFiveMember 2016-01-01 2016-09-30 0001307140 us-gaap:WarrantMember lmnk:HarcharanNarangMDMember 2016-01-01 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteOneMember lmnk:RoyMeadowsLoanAgreementMember 2016-01-01 2016-09-30 0001307140 us-gaap:WarrantMember lmnk:RoyMeadowsLoanAgreementMember us-gaap:SecuritiesFinancingTransactionFairValueMember 2016-01-01 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteFiveMember lmnk:DanielHagenMember 2016-01-01 2016-09-30 0001307140 us-gaap:SalesRevenueNetMember 2016-01-01 2016-09-30 0001307140 us-gaap:DirectorMember 2016-01-01 2016-09-30 0001307140 us-gaap:WarrantMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001307140 us-gaap:WarrantMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteSixMember 2016-01-01 2016-09-30 0001307140 us-gaap:WarrantMember lmnk:ConsultantsMember 2016-01-01 2016-09-30 0001307140 lmnk:LkbPartnersLlcMember 2016-01-01 2016-09-30 0001307140 lmnk:HarcharanNarangMDMember 2016-01-01 2016-09-30 0001307140 2016-09-30 0001307140 us-gaap:LicenseAgreementTermsMember 2016-09-30 0001307140 lmnk:MedCureCompaniesMember 2016-09-30 0001307140 lmnk:UnsecuredPromissoryNoteMember 2016-09-30 0001307140 lmnk:SecuredPromissoryNoteMember 2016-09-30 0001307140 lmnk:UnsecuredPromissoryNoteOneMember 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteMember 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteOneMember 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteTwoMember 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteThreeMember 2016-09-30 0001307140 us-gaap:WarrantMember 2016-09-30 0001307140 lmnk:SecuredPromissoryNoteOneMember 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteFourMember 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteFiveMember 2016-09-30 0001307140 us-gaap:WarrantMember lmnk:HarcharanNarangMDMember 2016-09-30 0001307140 lmnk:ConvertiblePromissoryNoteSixMember 2016-09-30 0001307140 us-gaap:WarrantMember lmnk:ConsultantsMember 2016-09-30 0001307140 us-gaap:WarrantMember lmnk:ConsultantsMember us-gaap:MinimumMember 2016-09-30 0001307140 us-gaap:WarrantMember lmnk:ConsultantsMember us-gaap:MaximumMember 2016-09-30 0001307140 us-gaap:SubsequentEventMember lmnk:ConvertiblePromissoryNoteFourMember lmnk:RoyMeadowsLoanAgreementMember 2016-10-13 0001307140 2016-11-18 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure lmnk:OutstandingLoan lmnk:Consultants LIFESTYLE MEDICAL NETWORK, INC. 0001307140 false --12-31 10-Q 2016-09-30 Q3 2016 Smaller Reporting Company 33958257 163 53824 49719 150869 516868 572850 5733 100000 677560 53107 311336 719694 1718348 134296 353213 242525 88893 83338 83338 80562 79174 937328 2393260 197877 266515 250000 525000 644065 858465 1091942 1649980 42512 1091942 1692492 33659 33959 9172696 10194495 -9360969 -9527686 -154614 700768 937328 2393260 105935 257055 0.001 0.001 200000000 200000000 33658257 33958257 33658257 33958257 7488 216000 379500 367500 935250 195339 195339 103500 206983 112500 326250 319500 586483 675339 1456839 108251 138035 202613 507220 -67894 -135914 -67894 -203682 161658 372810 135509 465023 58000 625335 -32611 47389 395803 1272094 373405 1223314 -76303 -685611 301934 233525 -61697 25000 32082 64532 161072 363545 -32082 -64532 -161072 -400242 -108385 -750143 140862 -166717 -108385 -750143 140862 -166717 -0.00 -0.02 0.00 -0.01 -0.00 -0.02 0.00 -0.01 33506609 32849658 33958257 33775410 33506609 32849658 45441075 33775410 18534 4164 17632 56083 116000 24000 625335 254095 257055 7488 310000 61715 84150 -79247 20901 127856 -345891 378710 -100000 135000 842560 80000 80000 265000 145448 -100448 -577560 42351 142351 30000 600000 330000 500000 300000 53661 101150 28750 999180 275000 116000 40000 418099 580000 <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 0.5in; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">1.</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></td></tr></table><p style="font: 10pt/15.33px 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">The consolidated balance sheet as of September 30, 2016 and the consolidated statements of operations, stockholders' deficiency and cash flows for the periods presented have been prepared by Lifestyle Medical Network, Inc. and Subsidiaries (the "Company" or "Lifestyle") and are unaudited. The consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods, and consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations, changes in stockholders' deficiency and cash flows for all periods presented have been made. The information for the consolidated balance sheet as of December 31, 2015 was derived from audited financial statements of the Company.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Organization</u></i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Lifestyle Medical Network Inc. and Subsidiaries (the &#8220;Company&#8221; or &#8220;Lifestyle&#8221;) was incorporated in the State of Nevada.&#160;&#160;The Company directs its operations through its subsidiaries.&#160;&#160;The Company, through its consulting subsidiaries, plans to continue to identify and enter into management and professional consulting services agreements, and to license medical and health technologies, to medical and health clinic operating companies. The Company also intends to open, operate and acquire medical and health clinics, if financing is available and the profile of the clinics&#8217; is favorable.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Material Agreements</u></i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company entered management agreements, and have commenced recognizing revenues thereunder, with two medical professional associations located in Houston, Texas, MED-Cure Primary Care Physicians, P.A. and MED-CURE Anti-Aging and Skin Care, P.A. (the &#8220;MED-CURE Companies&#8221;), effective April 1, 2015, which were purchased by Dr. Ronald Moomaw, a director of the Company. The MED-CURE Companies between them operate six medical clinics in Houston, of which four are primary care clinics and two are skin care clinics. Under management agreements with the MED-CURE Companies, the Company, through its subsidiary LifeStyle Texas Medical Management, LLC (&#8220;LifeStyle Management&#8221;), provides organizational development, accounting, human resources, computer technical support compliance, scheduling, marketing and advertising, office space, equipment supplies and other management services and receives an agreed percentage of the gross revenues of the practice group, with adjustments designed to ensure that management fees do not exceed an agreed cap, or that the monthly payments do not result in an event of default under the acquisition financing documents for the MED-CURE Companies. The leasing arrangements for the properties leased for the MED-CURE Companies&#8217; clinics&#8217; offices were restructured, with our real estate subsidiary, LifeStyle Texas Real Estate. LLC leasing the properties and then subleasing the properties back to the MED-CURE Companies.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Through our subsidiary, Regional Professional Alliance, Inc. , a physician&#8217;s professional consulting company that provides professional medical consulting services to medical management companies related to matters affecting professional licensure and medical clinic compliance matters for the benefit of clinics managed by Lifestyle Management, we have entered into an agreement with Dr. Moomaw to provide services through Regional Professional Alliance for the benefit of LifeStyle Management related to oversight and professional medical services coordination of the managed clinics which have entered into management services agreements with LifeStyle Management. Through LifeStyle Texas Licensing, LLC (&#8220;LifeStyle Licensing&#8221;), the Company plans to sublicense to the MED-CURE Companies the non-exclusive right to use, and to sublicense the use of, certain patents, trademarks, trade names, logos, slogans, trade dress, commercial symbols, operational systems, and other intellectual property rights, in connection with operating and managing medical clinics that provide medical services and/or products of a character and quality, in particular relating to men&#8217;s health and weight management.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>Going Concern</u></i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The consolidated financial statements for the period ended September 30, 2016 have been prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has a past history of recurring losses from operations and is a development stage company. The Company will require additional funding to execute its future strategic business plan. Successful business operations and its transition to attaining profitability are dependent upon obtaining additional financing and achieving a level of revenue to support its cost structure. These factors raise substantial doubt about the Company's ability to continue as a going concern.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company has entered into Management agreements with six medical clinics in Houston, Texas. The Company will provide services to the clinic and will receive an agreed percentage of gross revenues of the practice group. Management intends to make further acquisitions of other medical clinics during 2016.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Management believes these acquisitions will be profitable and the cash flows from these operations will enable the Company to fund the operations of the consolidated group over the next twelve months. Therefore, the annual financial statements continue to be prepared on a going concern basis.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Significant Accounting Policies</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">The Company&#8217;s significant accounting policies are summarized in Note 1 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2015. There were no significant changes to these accounting policies during the nine months ended September 30, 2016 and the Company does not expect that the adoption of other recent accounting pronouncements will have a material impact on its financial statements.</font></p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 0px; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">2.</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">INTANGIBLES</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><i><u>The MPL License Agreement</u></i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The MPL License Agreement, under which the Company's wholly-owned subsidiary, Elite, is the licensee pursuant to the Assignment from WMA, provides for the license of medical services, operational systems, manuals, certain names and logo designs and other intellectual property in connection with the operation of medical clinics that provide services related to men&#8217;s health within the territory of the continental United States (the &#8220;Licensed Rights&#8221;). The License Agreement provides for a fee of 6% of gross receipts of Licensee, payable quarterly. The term of the License Agreement is for twenty (20) years from the effective date, May 9, 2011. The Company plans to establish new medical clinics or acquire existing clinics, as well as to provide consulting services to medical clinics utilizing the Licensed Rights.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Intangibles are the value of the MPL license. Amounts assigned to this intangible were determined by management. Management considered a number of factors in determining the allocations, including valuations and independent appraisals. The intangibles are being amortized over 19.5 years, the life of the license.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The components of intangible assets are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="5">License Agreements</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="font-size: 10pt;">Balance January 1, 2015</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">88,893</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">Amortization for the year ended December 31, 2015</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(5,555</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">Balance December 31, 2015</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">83,338</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">Amortization for the nine months ended September 30, 2016</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(4,164</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">Balance September 30, 2016</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">79,174</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Amortization expense for the nine months ended September 30, 2016 and 2015 amounted to $4,164 and $4,165, respectively.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Estimated amortization expense for intangible assets for the next five years is as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">Year Ending</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">Amortization</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Expense</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">2016</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">1,391</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">2017</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,555</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">2018</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,555</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">2019</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,555</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">2020</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,555</td><td style="text-align: left; font-size: 10pt;"></td></tr></table></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">3.</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">LOAN RECEIVABLE-RELATED PARTY</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company advanced operating funds on a short-term basis to the MedCure Companies during the year ended December 31, 2015. The Company advanced the MedCure Companies $180,000 and received repayments of $80,000. During the nine months ended September 30, 2016, the Company advanced an additional $842,560 and received repayments of $265,000. As of September 30, 2016 and December 31, 2015, the MedCure Companies owed the Company $677,560 and $100,000, respectively.</font></p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">4</font></td><td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">PROPERTY AND EQUIPMENT</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Property and equipment consists of the following:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">September&#160;30,</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">December&#160;31,</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="font-size: 10pt;">Equipment</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">432,152</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">157,152</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Accumulated depreciation</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">78,939</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">22,856</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">353,213</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">134,296</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; color: red; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Depreciation expense for the nine months ended September 30, 2016 and 2015 was $56,083 and $16,632, respectively.</font></p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">5.</font></td><td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">DEBT</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Short-term debt as of September 30, 2016 and December 31, 2015 were as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;" colspan="2">September&#160;30,</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;" colspan="2">December&#160;31,</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2015</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"><u>Short-term Debt</u></td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Secured promissory note, interest @ 12% per annum, due June 30, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 82.66px; text-align: right; font-stretch: normal;">150,000</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 82.66px; text-align: right; font-stretch: normal;">150,000</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Unsecured promissory note, interest @ 10%, due June 30, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">75,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">75,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 10% per annum, due April 2, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">100,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">100,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 12% per annum, due April 28, 2017 and June 8, 2017 (2)</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">358,465</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">431,465</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 12% per annum, due December 17, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">100,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">100,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 10% per annum, due September 23, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">50,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">12,600</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Unsecured promissory note, interest @ 10% per annum, due November 1, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">25,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">25,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Secured promissory note, interest @ 6% per annum due April 1, 2017 (4)</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">275,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 12% per annum, due June 13, 2017 (3)</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">250,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 1.5pt; background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 12% per annum, due August 24, 2018 (5)</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">42,512</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">1,425,977</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">894,065</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 20pt; font-stretch: normal;">Less: Current portion</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">1,383,465</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">894,065</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 4pt; padding-left: 20pt; font-stretch: normal;">Long-term debt</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">42,512</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(1)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">On February 18, 2016, the Company executed an unsecured promissory note with Gail Keats and received $30,000. The promissory note is interest-free and is payable on or before August 15, 2016. The Company repaid the note in full in July 2016.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(2)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">On May 16, 2016, the Company amended its loan agreements with Roy Meadows (&#8220;Meadows&#8221;). The Company agreed to pay Meadows a renewal fee of $28,000 and $27,956 on its two outstanding loans with Meadows and extend the maturity dates of the loans to April 28, 2017 and June 8, 2017, respectively. The new outstanding balances of the loans including interest and the renewal fees amounted to $308,000 and $307,520, respectively.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">The Company also agreed to amend the conversion price of the loans into the Company&#8217;s common stock to $0.10 per share. At any time, the holder of the notes, at his option, shall have the right to convert the outstanding principal balance or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company. The fair value of the common stock at the date of issuance of the advance was $0.13, which created a Beneficial Conversion Feature of $409,766, the Beneficial Conversion Feature was recorded as a debt discount over the life of the notes. The debt discount as of September 30, 2016 was $257,055.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">The Company performed an analysis under ASC 470-50 criteria to determine if the note extension agreement falls under debt modification or debt extinguishment criteria. The Company revalued the warrants issued and agreed the additional consideration, extended maturity dates and interest to the extended agreement. The Company deems that based on the analysis performed, debt extinguishment does exist and recorded loss on debt extinguishment in the amount of $61,697.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(3)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">On June 13, 2016, the Company issued a convertible promissory note to Meadows and received proceeds of $250,000.The promissory note bears interest @ 12% per annum and matures one year from the date of issuance. On October 13, 2016, the promissory note was amended increasing the principal amount to $500,000 under the same terms and conditions of the promissory note for funds received in a second loan advance. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.15 per share.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(4)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On April 1, 2016, the Company issued a secured promissory note to Emile Fares, M,D, (the &#8220;Payee&#8221;) and promised to the Payee $275,000 in exchange for all the medical equipment owned by RMC Totalcare Medical PA.. The secured promissory note bears interest @ 6% per annum and matures one year from the date issuance. A payment of $75,000 is due October 1, 2016 and the balance due on the maturity date. The note is secured by all collections received by LifeStyle Texas Medical Management LLC pursuant to a Management Agreement with RMC Totoalcare Medical PA.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(5)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On August 24, 2016, the Company issued a convertible note to Daniel Hagen and received proceeds of $50,000. The promissory note bears interest @ 10% per annum and matures on August 24, 2018. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.06 per share. The fair value of the common stock at the date of issuance of the advance was $0.07, which created a Beneficial Conversion Feature of $8,333, the Beneficial Conversion Feature was recorded as a debt discount over the life of the note. The debt discount as of September 30, 2016 was $7,488.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Interest expense for the nine months ended September 30, 2016 and 2015 amounted to $107,484 and $64,532, respectively.</font></p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">6.</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">September&#160;30,</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">December&#160;31,</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="font-size: 10pt;">Interest</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">118,477</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">68,807</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">Salaries - Officer</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">-</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,125</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">Professional fees</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">98,221</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">64,306</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">Consulting</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">33,515</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">48,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">Other</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">16,302</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">15,639</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">266,515</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">197,877</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"></td></tr></table></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">7.</font></td><td><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">BASIC AND DILUTED EARNINGS PER SHARE</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Basic earnings per share are computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share are computed by dividing net earnings by the weighted-average number of common shares and dilutive potential common shares outstanding during the period. At September 30, 2016, there were 11,622,521 potential common shares. Because of the net loss, the effect of these potential common shares is anti-dilutive.</font></p></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">8.</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">WARRANTS</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">During September 2016, the Company issued warrants to four consultants to purchase 6,500,000 shares of the Company&#8217;s common stock at exercise prices of $0.07 and $0.08 per share. The warrants were issued in connection with services to be provided to the Company over the next two years. The fair value of the warrants were $500,000, of which $7,499 was expensed during the nine months ended September 30, 2016 and the balance of $492,501 is included in Prepaid expenses as of September 30, 2016.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On April 1, 2016, the Company issued a warrant to Harcharan Narang M.D, to purchase 800,000 shares of the Company&#8217;s common stock at an exercise price of $0.20 per share. The warrant was issued in connection with services provided to the Company. The fair value of the warrant was $80,000, of which $39,890 was expensed during the nine months ended September 30, 2016 and the balance of $40,110 is included in prepaid expenses at September 30, 2016.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On May 16, 2016, the Company issued a warrant to Roy Meadows to purchase 1,059,564 shares of the Company&#8217;s common stock at an exercise price of $0.025 per share. The purchase warrant consist of a bonus warrant of 500,000 shares and a renewal warrant of 559,564 shares issued in connection with the extension of two Meadows&#8217; notes. The fair value of the warrants amounted to $112,555. This amount has been included with the debt discount against the Roy Meadows noteand will be amortized over the life of the note.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On June 13, 2016, the Company issued a warrant to Roy Meadows to purchase 250,000 shares of the Company&#8217;s common stock at an exercise price of $0.025 per share. The warrant was issued in connection with a financing provided to the Company. The fair value of the warrant was $17,500, of which $5,104 was expensed during the nine months ended September 30, 2016.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The estimated value of the warrants was determined using the Black Scholes pricing model using the following assumptions: expected term of 5 to 7 years, a risk free interest rate between 1.39% and 1.56%, a dividend yield of -0- and volatility between 202% and 424%. The fair value of the warrants amounted to $708,910.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company's common stock issued to non-employees of the Company. The warrants were granted in lieu of cash compensation for services performed.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">Exercise</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;">Remaining</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">Intrinsic</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Shares</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Price</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Life</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Value</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="font-size: 10pt;">Outstanding, January 1, 2016</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">8,000,000</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">0.13</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 103.33px; text-align: right; font-size: 10pt;">4.6</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">Granted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">8,609,564</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0.08</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5.0</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">Expired/Cancelled</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">-</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">-</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">Exercised</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">Outstanding-period ending September 30, 2016</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">16,609,564</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.12</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt; font-size: 10pt;">4.8 years</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">81,430</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">Exercisable-period ending September 30, 2016</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">16,609,564</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.12</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt; font-size: 10pt;">4.8 years</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">81,430</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"></td></tr></table></div> <div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">9.</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">RELATED PARTY TRANSACTIONS</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">a) Dr. Ronald Moomaw (&#8220;Moomaw&#8221;), a director of the Company, is the sole owner of the MED-CURE Companies. The Company received a majority of its revenue for the nine months ended September 30, 2016 from the MED-Cure Companies.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">In connection with the management of the Med-Cure Companies, Moomaw was issued a warrant for the purchase of 5,000,000 shares of the Company&#63;s common stock valued @ $465,000, the fair value at the time of issuance, April 17, 2015. &#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">Moomaw also received consulting fees of $114,800 and $39,600 for the nine months ended September 30, 2016 and 2015, respectively, as part of his management compensation. &#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">b) The Company advanced operating funds on a short-term basis to the MED-CURE Companies and received payments during the nine months ended September 30, 2016 and the year ended December 31, 2015. As of September 30, 2016 and December 31, 2015, the MED-CURE Companies owe the Company $677,560 and $100,000, respectively.</p></div> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 36pt; line-height: 15.3333320617676px; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">10.</font></td> <td style="text-align: justify; line-height: 15.3333320617676px; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">COMMON STOCK</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;">&#160;</p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify;">On June 15, 2016, the Company issued 100,000 shares of the Company&#8217;s common stock to LKB Partners LLC in connection with a service agreement with the Company. The fair value of the common stock issued was $8,000, of which $6,000 was expensed during the nine months ended September 30, 2016.</p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;">&#160;</p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 0.5in; text-align: justify;">On June 15, 2016, the Company issued 200,000 shares of the Company&#8217;s common stock to Harcharan Narang M.D. in connection with a service agreement with the Company. The fair value of the common stock issued was $16,000, all of which was expensed during the nine months ended September 30, 2016.</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> <td style="width: 36pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">11.</font></td> <td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">MAJOR CUSTOMERS</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 36pt; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">87% of the revenues for the nine months ended September 30, 2016, was received from companies owned 100% by Dr. Ronald Moomaw, a director of the Company.</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> <td style="width: 36pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">12.</font></td> <td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">COMMITMENTS AND CONTINGENCIES</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 36pt; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Consulting Agreements</font></p> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 36pt; text-align: justify; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> <td style="width: 36pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px;"></td> <td style="width: 18pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">a)</font></td> <td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">During 2015 and 2014, Lifestyle entered into various consulting agreements with third parties in connection with business advisory services. For the nine months ended September 30, 2016 and 2015, consulting services amounted to $190,579 and $111,187, respectively.</font></td> </tr> </table> <p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px 0px 0px 54pt; text-align: justify; background-color: white;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"> <td style="width: 36pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px;"></td> <td style="width: 18pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">b)</font></td> <td style="text-align: justify; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-top: 0px; padding-bottom: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">On July 1, 2012, Lifestyle entered into an employment agreement with Christopher Smith("Smith"), the Company's Chief Executive Officer. The term of the agreement is for five years. Effective August 1, 2015, the monthly salary for Smith was increased to $12,500. Smith will also receive a performance bonus based on a percentage of the Company's net operating profit before income taxes. For the nine months ended September 30, 2016, and 2015, payroll-officer amounted to $112,500 and $60,000, respectively.</font></td> </tr> </table> <div><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; font-size: 10pt;" colspan="5"><br class="apple-interchange-newline" />License Agreements</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="font-size: 10pt;">Balance January 1, 2015</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">88,893</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">Amortization for the year ended December 31, 2015</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(5,555</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">Balance December 31, 2015</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">83,338</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">Amortization for the nine months ended September 30, 2016</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(4,164</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">Balance September 30, 2016</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">79,174</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"></td></tr></table></div> <div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">Year Ending</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">Amortization</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">December 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Expense</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">2016</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">1,391</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">2017</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,555</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">2018</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,555</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">2019</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,555</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">2020</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5,555</td><td style="text-align: left; font-size: 10pt;"></td></tr></table></div> <div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">September&#160;30,</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">December&#160;31,</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="font-size: 10pt;">Equipment</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">432,152</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">157,152</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">Accumulated depreciation</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">78,939</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">22,856</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">353,213</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">134,296</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"></td></tr></table></div> <div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;" colspan="2">September&#160;30,</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; font-stretch: normal;" colspan="2">December&#160;31,</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2016</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">2015</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"><u>Short-term Debt</u></td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Secured promissory note, interest @ 12% per annum, due June 30, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 82.66px; text-align: right; font-stretch: normal;">150,000</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; text-align: left; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 82.66px; text-align: right; font-stretch: normal;">150,000</td><td style="font: 10pt/normal 'times new roman', times, serif; width: 10px; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Unsecured promissory note, interest @ 10%, due June 30, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">75,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">75,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 10% per annum, due April 2, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">100,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">100,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 12% per annum, due April 28, 2017 and June 8, 2017 (2)</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">358,465</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">431,465</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 12% per annum, due December 17, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">100,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">100,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 10% per annum, due September 23, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">50,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">12,600</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Unsecured promissory note, interest @ 10% per annum, due November 1, 2016</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">25,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">25,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Secured promissory note, interest @ 6% per annum due April 1, 2017 (4)</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">275,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 12% per annum, due June 13, 2017 (3)</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">250,000</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 1.5pt; background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 20pt; font-stretch: normal;">Convertible promissory note, interest @ 12% per annum, due August 24, 2018 (5)</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">42,512</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: -10pt; padding-left: 20pt; font-size: 10pt;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">1,425,977</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">894,065</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 20pt; font-stretch: normal;">Less: Current portion</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">1,383,465</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">894,065</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: -10pt; padding-bottom: 4pt; padding-left: 20pt; font-stretch: normal;">Long-term debt</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">42,512</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(1)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">On February 18, 2016, the Company executed an unsecured promissory note with Gail Keats and received $30,000. The promissory note is interest-free and is payable on or before August 15, 2016. The Company repaid the note in full in July 2016.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(2)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">On May 16, 2016, the Company amended its loan agreements with Roy Meadows (&#8220;Meadows&#8221;). The Company agreed to pay Meadows a renewal fee of $28,000 and $27,956 on its two outstanding loans with Meadows and extend the maturity dates of the loans to April 28, 2017 and June 8, 2017, respectively. The new outstanding balances of the loans including interest and the renewal fees amounted to $308,000 and $307,520, respectively.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">The Company also agreed to amend the conversion price of the loans into the Company&#8217;s common stock to $0.10 per share. At any time, the holder of the notes, at his option, shall have the right to convert the outstanding principal balance or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company. The fair value of the common stock at the date of issuance of the advance was $0.13, which created a Beneficial Conversion Feature of $409,766, the Beneficial Conversion Feature was recorded as a debt discount over the life of the notes. The debt discount as of September 30, 2016 was $257,055.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">The Company performed an analysis under ASC 470-50 criteria to determine if the note extension agreement falls under debt modification or debt extinguishment criteria. The Company revalued the warrants issued and agreed the additional consideration, extended maturity dates and interest to the extended agreement. The Company deems that based on the analysis performed, debt extinguishment does exist and recorded loss on debt extinguishment in the amount of $61,697.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 72pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(3)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">On June 13, 2016, the Company issued a convertible promissory note to Meadows and received proceeds of $250,000.The promissory note bears interest @ 12% per annum and matures one year from the date of issuance. On October 13, 2016, the promissory note was amended increasing the principal amount to $500,000 under the same terms and conditions of the promissory note for funds received in a second loan advance. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.15 per share.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(4)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On April 1, 2016, the Company issued a secured promissory note to Emile Fares, M,D, (the &#8220;Payee&#8221;) and promised to the Payee $275,000 in exchange for all the medical equipment owned by RMC Totalcare Medical PA.. The secured promissory note bears interest @ 6% per annum and matures one year from the date issuance. A payment of $75,000 is due October 1, 2016 and the balance due on the maturity date. The note is secured by all collections received by LifeStyle Texas Medical Management LLC pursuant to a Management Agreement with RMC Totoalcare Medical PA.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 36pt; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">(5)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: justify; padding-top: 0px; padding-bottom: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On August 24, 2016, the Company issued a convertible note to Daniel Hagen and received proceeds of $50,000. The promissory note bears interest @ 10% per annum and matures on August 24, 2018. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.06 per share. The fair value of the common stock at the date of issuance of the advance was $0.07, which created a Beneficial Conversion Feature of $8,333, the Beneficial Conversion Feature was recorded as a debt discount over the life of the note. The debt discount as of September 30, 2016 was $7,488.</font></td></tr></table></div> <div><br class="apple-interchange-newline" /><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">September&#160;30,</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">December&#160;31,</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="font-size: 10pt;">Interest</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">118,477</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">68,807</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">Salaries - Officer</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">-</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">1,125</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-align: left; font-size: 10pt;">Professional fees</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">98,221</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">64,306</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">Consulting</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">33,515</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">48,000</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">Other</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">16,302</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">15,639</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">266,515</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">197,877</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"></td></tr></table></div> <div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table align="center" style="width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;" colspan="2">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">Exercise</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;">Remaining</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt;" colspan="2">Intrinsic</td><td style="font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Shares</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Price</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Life</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Value</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="font-size: 10pt;">Outstanding, January 1, 2016</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">8,000,000</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">$</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">0.13</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 103.33px; text-align: right; font-size: 10pt;">4.6</td><td style="width: 10px; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td><td style="width: 82.66px; text-align: right; font-size: 10pt;">&#160;</td><td style="width: 10px; text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">Granted</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">8,609,564</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">0.08</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">5.0</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="font-size: 10pt;">Expired/Cancelled</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">-</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">-</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td><td style="text-align: right; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">Exercised</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">Outstanding-period ending September 30, 2016</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">16,609,564</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.12</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt; font-size: 10pt;">4.8 years</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">81,430</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">Exercisable-period ending September 30, 2016</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">16,609,564</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.12</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: right; padding-bottom: 4pt; font-size: 10pt;">4.8 years</td><td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td><td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">81,430</td><td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"></td></tr></table></div> 1391 5555 5555 5555 5555 0.06 P20Y P19Y6M 180000 842560 157152 432152 22856 78939 894065 75000 150000 25000 100000 431465 100000 12600 1425977 75000 150000 25000 100000 358465 100000 50000 275000 250000 42512 -894065 -1383465 42512 42512 0.06 0.12 0.10 0.10 0.12 0.10 0.10 0.12 0.12 0.10 0.12 0.12 0.12 2016-10-01 2017-04-28 2017-06-08 2018-08-24 2016-06-30 2016-06-30 2016-11-01 2016-04-02 2017-04-28 2016-12-17 2016-09-23 2017-06-13 2018-08-24 2017-06-08 28000 27956 308000 307520 2 0.10 0.15 0.06 0.13 0.07 40000 409766 8333 426121 275000 30000 250000 50000 75000 64532 107484 500000 68807 118477 1125 64306 98221 48000 33515 15639 16302 11622521 8000000 16609564 8609564 16609564 0.13 0.12 0.08 0.12 P4Y7M6D P5Y P4Y9M18D P4Y9M18D 81430 81430 800000 1059564 250000 5000000 6500000 0.20 0.025 0.025 0.07 0.08 500000 559564 80000 112555 708910 17500 500000 39890 5104 7499 P7Y P5Y 0.0156 0.0139 0.00 4.24 2.02 4 40110 492501 465000 39600 114800 100000 200000 8000 16000 6000 0.87 1.00 111187 190579 P5Y 60000 112500 12500 On May 16, 2016, the Company amended its loan agreements with Roy Meadows ("Meadows"). The Company agreed to pay Meadows a renewal fee of $28,000 and $27,956 on its two outstanding loans with Meadows and extend the maturity dates of the loans to April 28, 2017 and June 8, 2017, respectively. The new outstanding balances of the loans including interest and the renewal fees amounted to $308,000 and $307,520, respectively. The Company also agreed to amend the conversion price of the loans into the Company's common stock to $0.10 per share. At any time, the holder of the notes, at his option, shall have the right to convert the outstanding principal balance or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company. The fair value of the common stock at the date of issuance of the advance was $0.13, which created a Beneficial Conversion Feature of $409,766, the Beneficial Conversion Feature was recorded as a debt discount over the life of the notes. The debt discount as of September 30, 2016 was $257,055. The Company performed an analysis under ASC 470-50 criteria to determine if the note extension agreement falls under debt modification or debt extinguishment criteria. The Company revalued the warrants issued and agreed the additional consideration, extended maturity dates and interest to the extended agreement. The Company deems that based on the analysis performed, debt extinguishment does exist and recorded loss on debt extinguishment in the amount of $61,697. On April 1, 2016, the Company issued a secured promissory note to Emile Fares, M,D, (the "Payee") and promised to the Payee $275,000 in exchange for all the medical equipment owned by RMC Totalcare Medical PA.. The secured promissory note bears interest @ 6% per annum and matures one year from the date issuance. A payment of $75,000 is due October 1, 2016 and the balance due on the maturity date. The note is secured by all collections received by LifeStyle Texas Medical Management LLC pursuant to a Management Agreement with RMC Totoalcare Medical PA. On June 13, 2016, the Company issued a convertible promissory note to Meadows and received proceeds of $250,000.The promissory note bears interest @ 12% per annum and matures one year from the date of issuance. On October 13, 2016, the promissory note was amended increasing the principal amount to $500,000 under the same terms and conditions of the promissory note for funds received in a second loan advance. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.15 per share. On August 24, 2016, the Company issued a convertible note to Daniel Hagen and received proceeds of $50,000. The promissory note bears interest @ 10% per annum and matures on August 24, 2018. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.06 per share. The fair value of the common stock at the date of issuance of the advance was $0.07, which created a Beneficial Conversion Feature of $8,333, the Beneficial Conversion Feature was recorded as a debt discount over the life of the note. The debt discount as of September 30, 2016 was $7,488. EX-101.SCH 5 lmnk-20160930.xsd XBRL SCHEMA FILE 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Description of Business and Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Intangibles link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Loan Receivable-Related Party link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Basic and Diluted Earnings per Share link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Warrants link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Common Stock link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Major Customers link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Intangibles (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Intangibles (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Intangibles (Details 1) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Intangibles (Details Textual) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Loan Receivable-Related Party (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Debt (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Debt (Details Textual) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Basic and Diluted Earnings per Share (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Warrants (Details Textual) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Common Stock (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Major Customers (Details) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 lmnk-20160930_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 lmnk-20160930_def.xml XBRL DEFINITION FILE EX-101.LAB 8 lmnk-20160930_lab.xml XBRL LABEL FILE EX-101.PRE 9 lmnk-20160930_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2016
Nov. 18, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name LIFESTYLE MEDICAL NETWORK, INC.  
Entity Central Index Key 0001307140  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Type 10-Q  
Document Period End Date Sep. 30, 2016  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2016  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   33,958,257
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Balance Sheets - USD ($)
Sep. 30, 2016
Dec. 31, 2015
CURRENT ASSETS:    
Cash and cash equivalents $ 150,869 $ 49,719
Accounts receivable-related party 572,850 516,868
Accounts receivable 5,733
Loan receivable-related party 677,560 100,000
Prepaid expenses 311,336 53,107
Total Current Assets 1,718,348 719,694
Property, plant and equipment - net 353,213 134,296
Other assets 242,525
Intangible assets - net 80,562 83,338
TOTAL ASSETS 2,393,260 937,328
CURRENT LIABILITIES:    
Accounts payable and accrued expenses 266,515 197,877
Notes payable 525,000 250,000
Convertible notes payable,net of $257,055 and $105,935 debt discount 858,465 644,065
Total Current Liabilities 1,649,980 1,091,942
LONG-TERM LIABILITIES:    
Convertible notes payable,net of $7,488 debt discount 42,512
Total Liabilities 1,692,492 1,091,942
Commitments and Contingencies
STOCKHOLDERS' EQUITY (DEFICIENCY):    
Common stock, $.001 par value, 200,000,000 shares authorized; 33,958,257 and 33,658,257 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively 33,959 33,659
Additional paid-in-capital 10,194,495 9,172,696
Accumulated deficit (9,527,686) (9,360,969)
Total Stockholders' Equity (Deficiency) 700,768 (154,614)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) $ 2,393,260 $ 937,328
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Balance Sheets (Parenthetical) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Balance Sheets    
Net of debt discount $ 257,055 $ 105,935
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 33,958,257 33,658,257
Common stock, shares outstanding 33,958,257 33,658,257
Debt discount- Long term $ 7,488  
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenues:        
Management fees-related party $ 367,500 $ 216,000 $ 935,250 $ 379,500
Management fees 195,339 195,339
Rental income-related party 112,500 103,500 326,250 206,983
Total revenues 675,339 319,500 1,456,839 586,483
Costs and expenses:        
Cost of revenue related to management fees 202,613 108,251 507,220 138,035
Cost of revenue related to rental income 67,894 67,894 203,682 135,914
Selling, general and administrative expenses 135,509 161,658 465,023 372,810
Amortization of warrants (32,611) 58,000 47,389 625,335
Total Costs and expenses 373,405 395,803 1,223,314 1,272,094
Income (loss) from operations 301,934 (76,303) 233,525 (685,611)
Other income (expense):        
Loss on extinguishment of debt (61,697)
Other income 25,000
Interest expense (161,072) (32,082) (363,545) (64,532)
Total Other income (expense) (161,072) (32,082) (400,242) (64,532)
Income (loss) from operations before provision for income taxes 140,862 (108,385) (166,717) (750,143)
Provision for income taxes
Net income (loss) $ 140,862 $ (108,385) $ (166,717) $ (750,143)
Income (loss) per common share-basic $ 0.00 $ (0.00) $ (0.01) $ (0.02)
Income (loss) per common share- diluted $ 0.00 $ (0.00) $ (0.01) $ (0.02)
Weighted average common shares outstanding - basic 33,958,257 33,506,609 33,775,410 32,849,658
Weighted average common shares outstanding - diluted 45,441,075 33,506,609 33,775,410 32,849,658
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash flows from operating activities:    
Net loss $ (166,717) $ (750,143)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of intangible assets 4,164 18,534
Depreciation 56,083 17,632
Loss on extinguishment of debt 61,697
Stock-based compensation 24,000 116,000
Amortization of debt discount 254,095 625,335
Changes in operating assets and liabilities:    
Accounts receivable (61,715) (310,000)
Prepaid expenses 79,247 (84,150)
Accounts payable and accrued expenses 127,856 20,901
Net Cash Provided by (used in) Operating Activities 378,710 (345,891)
Cash flows from investing activities:    
Refund of deposit 100,000
Advances to related party (842,560) (135,000)
Repayments by related party 265,000 80,000
Purchase of equipment (145,448)
Net Cash Used In Investing Activities (577,560) (100,448)
Cash flows from financing activities:    
Proceeds from related parties 42,351
Repayment of related party debt (142,351)
Repayment of short-term debt (30,000)
Proceeds from short-term debt 330,000 600,000
Net Cash Provided by Financing Activities 300,000 500,000
Net change in cash 101,150 53,661
Cash and cash equivalents - Beginning of period 49,719 163
Cash and cash equivalents - End of period 150,869 53,824
Cash paid for:    
Interest 28,750
Income taxes
Non-cash Investing and Financing Activities    
Conversion of debt and interest for common stock 999,180
Equipment purchased with notes payable 275,000
Issuance of common stock for services 116,000
Beneficial conversion feature 418,099 40,000
Issuance of warrants for prepaid services $ 580,000
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Description of Business and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2016
Description of Business and Summary of Significant Accounting Policies [Abstract]  
DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
1.DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The consolidated balance sheet as of September 30, 2016 and the consolidated statements of operations, stockholders' deficiency and cash flows for the periods presented have been prepared by Lifestyle Medical Network, Inc. and Subsidiaries (the "Company" or "Lifestyle") and are unaudited. The consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods, and consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations, changes in stockholders' deficiency and cash flows for all periods presented have been made. The information for the consolidated balance sheet as of December 31, 2015 was derived from audited financial statements of the Company.

 

Organization

 

Lifestyle Medical Network Inc. and Subsidiaries (the “Company” or “Lifestyle”) was incorporated in the State of Nevada.  The Company directs its operations through its subsidiaries.  The Company, through its consulting subsidiaries, plans to continue to identify and enter into management and professional consulting services agreements, and to license medical and health technologies, to medical and health clinic operating companies. The Company also intends to open, operate and acquire medical and health clinics, if financing is available and the profile of the clinics’ is favorable.

 

Material Agreements

 

The Company entered management agreements, and have commenced recognizing revenues thereunder, with two medical professional associations located in Houston, Texas, MED-Cure Primary Care Physicians, P.A. and MED-CURE Anti-Aging and Skin Care, P.A. (the “MED-CURE Companies”), effective April 1, 2015, which were purchased by Dr. Ronald Moomaw, a director of the Company. The MED-CURE Companies between them operate six medical clinics in Houston, of which four are primary care clinics and two are skin care clinics. Under management agreements with the MED-CURE Companies, the Company, through its subsidiary LifeStyle Texas Medical Management, LLC (“LifeStyle Management”), provides organizational development, accounting, human resources, computer technical support compliance, scheduling, marketing and advertising, office space, equipment supplies and other management services and receives an agreed percentage of the gross revenues of the practice group, with adjustments designed to ensure that management fees do not exceed an agreed cap, or that the monthly payments do not result in an event of default under the acquisition financing documents for the MED-CURE Companies. The leasing arrangements for the properties leased for the MED-CURE Companies’ clinics’ offices were restructured, with our real estate subsidiary, LifeStyle Texas Real Estate. LLC leasing the properties and then subleasing the properties back to the MED-CURE Companies.

 

Through our subsidiary, Regional Professional Alliance, Inc. , a physician’s professional consulting company that provides professional medical consulting services to medical management companies related to matters affecting professional licensure and medical clinic compliance matters for the benefit of clinics managed by Lifestyle Management, we have entered into an agreement with Dr. Moomaw to provide services through Regional Professional Alliance for the benefit of LifeStyle Management related to oversight and professional medical services coordination of the managed clinics which have entered into management services agreements with LifeStyle Management. Through LifeStyle Texas Licensing, LLC (“LifeStyle Licensing”), the Company plans to sublicense to the MED-CURE Companies the non-exclusive right to use, and to sublicense the use of, certain patents, trademarks, trade names, logos, slogans, trade dress, commercial symbols, operational systems, and other intellectual property rights, in connection with operating and managing medical clinics that provide medical services and/or products of a character and quality, in particular relating to men’s health and weight management.

 

Going Concern

 

The consolidated financial statements for the period ended September 30, 2016 have been prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has a past history of recurring losses from operations and is a development stage company. The Company will require additional funding to execute its future strategic business plan. Successful business operations and its transition to attaining profitability are dependent upon obtaining additional financing and achieving a level of revenue to support its cost structure. These factors raise substantial doubt about the Company's ability to continue as a going concern.

 

The Company has entered into Management agreements with six medical clinics in Houston, Texas. The Company will provide services to the clinic and will receive an agreed percentage of gross revenues of the practice group. Management intends to make further acquisitions of other medical clinics during 2016.

 

Management believes these acquisitions will be profitable and the cash flows from these operations will enable the Company to fund the operations of the consolidated group over the next twelve months. Therefore, the annual financial statements continue to be prepared on a going concern basis.

 

Significant Accounting Policies

 

The Company’s significant accounting policies are summarized in Note 1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. There were no significant changes to these accounting policies during the nine months ended September 30, 2016 and the Company does not expect that the adoption of other recent accounting pronouncements will have a material impact on its financial statements.
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangibles
 9 Months Ended
Sep. 30, 2016
Intangibles [Abstract]  
INTANGIBLES
2.INTANGIBLES

 

The MPL License Agreement

 

The MPL License Agreement, under which the Company's wholly-owned subsidiary, Elite, is the licensee pursuant to the Assignment from WMA, provides for the license of medical services, operational systems, manuals, certain names and logo designs and other intellectual property in connection with the operation of medical clinics that provide services related to men’s health within the territory of the continental United States (the “Licensed Rights”). The License Agreement provides for a fee of 6% of gross receipts of Licensee, payable quarterly. The term of the License Agreement is for twenty (20) years from the effective date, May 9, 2011. The Company plans to establish new medical clinics or acquire existing clinics, as well as to provide consulting services to medical clinics utilizing the Licensed Rights.

 

Intangibles are the value of the MPL license. Amounts assigned to this intangible were determined by management. Management considered a number of factors in determining the allocations, including valuations and independent appraisals. The intangibles are being amortized over 19.5 years, the life of the license.

 

The components of intangible assets are as follows:

 

 License Agreements
     
 Balance January 1, 2015 $88,893 
      
 Amortization for the year ended December 31, 2015  (5,555)
      
 Balance December 31, 2015  83,338 
      
 Amortization for the nine months ended September 30, 2016  (4,164)
      
 Balance September 30, 2016 $79,174 

 

Amortization expense for the nine months ended September 30, 2016 and 2015 amounted to $4,164 and $4,165, respectively.

 

Estimated amortization expense for intangible assets for the next five years is as follows:

 

 Year Ending Amortization 
 December 31, Expense 
 2016  1,391 
 2017  5,555 
 2018  5,555 
 2019  5,555 
 2020  5,555
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Loan Receivable-Related Party
 9 Months Ended
Sep. 30, 2016
Loan Receivable-Related Party [Abstract]  
LOAN RECEIVABLE-RELATED PARTY
3.LOAN RECEIVABLE-RELATED PARTY

 

The Company advanced operating funds on a short-term basis to the MedCure Companies during the year ended December 31, 2015. The Company advanced the MedCure Companies $180,000 and received repayments of $80,000. During the nine months ended September 30, 2016, the Company advanced an additional $842,560 and received repayments of $265,000. As of September 30, 2016 and December 31, 2015, the MedCure Companies owed the Company $677,560 and $100,000, respectively.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment
 9 Months Ended
Sep. 30, 2016
Property and Equipment [Abstract]  
PROPERTY AND EQUIPMENT
4PROPERTY AND EQUIPMENT

 

Property and equipment consists of the following:

 

   September 30,  December 31, 
   2016  2015 
 Equipment $432,152  $157,152 
 Accumulated depreciation  78,939   22,856 
   $353,213  $134,296 

 

Depreciation expense for the nine months ended September 30, 2016 and 2015 was $56,083 and $16,632, respectively.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt
 9 Months Ended
Sep. 30, 2016
Debt [Abstract]  
DEBT
5.DEBT

 

Short-term debt as of September 30, 2016 and December 31, 2015 were as follows:

 

   September 30,  December 31, 
   2016  2015 
 Short-term Debt      
        
 Secured promissory note, interest @ 12% per annum, due June 30, 2016 $150,000  $150,000 
          
 Unsecured promissory note, interest @ 10%, due June 30, 2016  75,000   75,000 
          
 Convertible promissory note, interest @ 10% per annum, due April 2, 2016  100,000   100,000 
          
 Convertible promissory note, interest @ 12% per annum, due April 28, 2017 and June 8, 2017 (2)  358,465   431,465 
          
 Convertible promissory note, interest @ 12% per annum, due December 17, 2016  100,000   100,000 
          
 Convertible promissory note, interest @ 10% per annum, due September 23, 2016  50,000   12,600 
          
 Unsecured promissory note, interest @ 10% per annum, due November 1, 2016  25,000   25,000 
          
 Secured promissory note, interest @ 6% per annum due April 1, 2017 (4)  275,000   - 
          
 Convertible promissory note, interest @ 12% per annum, due June 13, 2017 (3)  250,000   - 
          
 Convertible promissory note, interest @ 12% per annum, due August 24, 2018 (5)  42,512   - 
    1,425,977   894,065 
 Less: Current portion  1,383,465   894,065 
 Long-term debt $42,512  $- 

 

(1)On February 18, 2016, the Company executed an unsecured promissory note with Gail Keats and received $30,000. The promissory note is interest-free and is payable on or before August 15, 2016. The Company repaid the note in full in July 2016.

 

(2)On May 16, 2016, the Company amended its loan agreements with Roy Meadows (“Meadows”). The Company agreed to pay Meadows a renewal fee of $28,000 and $27,956 on its two outstanding loans with Meadows and extend the maturity dates of the loans to April 28, 2017 and June 8, 2017, respectively. The new outstanding balances of the loans including interest and the renewal fees amounted to $308,000 and $307,520, respectively.

 

The Company also agreed to amend the conversion price of the loans into the Company’s common stock to $0.10 per share. At any time, the holder of the notes, at his option, shall have the right to convert the outstanding principal balance or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company. The fair value of the common stock at the date of issuance of the advance was $0.13, which created a Beneficial Conversion Feature of $409,766, the Beneficial Conversion Feature was recorded as a debt discount over the life of the notes. The debt discount as of September 30, 2016 was $257,055.

 

The Company performed an analysis under ASC 470-50 criteria to determine if the note extension agreement falls under debt modification or debt extinguishment criteria. The Company revalued the warrants issued and agreed the additional consideration, extended maturity dates and interest to the extended agreement. The Company deems that based on the analysis performed, debt extinguishment does exist and recorded loss on debt extinguishment in the amount of $61,697.

 

(3)On June 13, 2016, the Company issued a convertible promissory note to Meadows and received proceeds of $250,000.The promissory note bears interest @ 12% per annum and matures one year from the date of issuance. On October 13, 2016, the promissory note was amended increasing the principal amount to $500,000 under the same terms and conditions of the promissory note for funds received in a second loan advance. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.15 per share.

 

(4)On April 1, 2016, the Company issued a secured promissory note to Emile Fares, M,D, (the “Payee”) and promised to the Payee $275,000 in exchange for all the medical equipment owned by RMC Totalcare Medical PA.. The secured promissory note bears interest @ 6% per annum and matures one year from the date issuance. A payment of $75,000 is due October 1, 2016 and the balance due on the maturity date. The note is secured by all collections received by LifeStyle Texas Medical Management LLC pursuant to a Management Agreement with RMC Totoalcare Medical PA.

 

(5)On August 24, 2016, the Company issued a convertible note to Daniel Hagen and received proceeds of $50,000. The promissory note bears interest @ 10% per annum and matures on August 24, 2018. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.06 per share. The fair value of the common stock at the date of issuance of the advance was $0.07, which created a Beneficial Conversion Feature of $8,333, the Beneficial Conversion Feature was recorded as a debt discount over the life of the note. The debt discount as of September 30, 2016 was $7,488.

 

Interest expense for the nine months ended September 30, 2016 and 2015 amounted to $107,484 and $64,532, respectively.
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounts Payable and Accrued Expenses
 9 Months Ended
Sep. 30, 2016
Accounts Payable and Accrued Expenses [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
6.ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

   September 30,  December 31, 
   2016  2015 
 Interest $118,477  $68,807 
 Salaries - Officer  -   1,125 
 Professional fees  98,221   64,306 
 Consulting  33,515   48,000 
 Other  16,302   15,639 
   $266,515  $197,877
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basic and Diluted Earnings per Share
 9 Months Ended
Sep. 30, 2016
Basic and Diluted Earnings per Share [Abstract]  
BASIC AND DILUTED EARNINGS PER SHARE
7.BASIC AND DILUTED EARNINGS PER SHARE

 

Basic earnings per share are computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share are computed by dividing net earnings by the weighted-average number of common shares and dilutive potential common shares outstanding during the period. At September 30, 2016, there were 11,622,521 potential common shares. Because of the net loss, the effect of these potential common shares is anti-dilutive.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants
 9 Months Ended
Sep. 30, 2016
Warrants [Abstract]  
WARRANTS
8.WARRANTS

 

During September 2016, the Company issued warrants to four consultants to purchase 6,500,000 shares of the Company’s common stock at exercise prices of $0.07 and $0.08 per share. The warrants were issued in connection with services to be provided to the Company over the next two years. The fair value of the warrants were $500,000, of which $7,499 was expensed during the nine months ended September 30, 2016 and the balance of $492,501 is included in Prepaid expenses as of September 30, 2016.

 

On April 1, 2016, the Company issued a warrant to Harcharan Narang M.D, to purchase 800,000 shares of the Company’s common stock at an exercise price of $0.20 per share. The warrant was issued in connection with services provided to the Company. The fair value of the warrant was $80,000, of which $39,890 was expensed during the nine months ended September 30, 2016 and the balance of $40,110 is included in prepaid expenses at September 30, 2016.

 

On May 16, 2016, the Company issued a warrant to Roy Meadows to purchase 1,059,564 shares of the Company’s common stock at an exercise price of $0.025 per share. The purchase warrant consist of a bonus warrant of 500,000 shares and a renewal warrant of 559,564 shares issued in connection with the extension of two Meadows’ notes. The fair value of the warrants amounted to $112,555. This amount has been included with the debt discount against the Roy Meadows noteand will be amortized over the life of the note.

 

On June 13, 2016, the Company issued a warrant to Roy Meadows to purchase 250,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The warrant was issued in connection with a financing provided to the Company. The fair value of the warrant was $17,500, of which $5,104 was expensed during the nine months ended September 30, 2016.

 

The estimated value of the warrants was determined using the Black Scholes pricing model using the following assumptions: expected term of 5 to 7 years, a risk free interest rate between 1.39% and 1.56%, a dividend yield of -0- and volatility between 202% and 424%. The fair value of the warrants amounted to $708,910.

  

The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company's common stock issued to non-employees of the Company. The warrants were granted in lieu of cash compensation for services performed.

 

      Exercise  Remaining Intrinsic 
   Shares  Price  Life Value 
 Outstanding, January 1, 2016  8,000,000  $0.13  4.6    
 Granted  8,609,564   0.08  5.0    
 Expired/Cancelled  -   -       
 Exercised  -   -       
 Outstanding-period ending September 30, 2016  16,609,564  $0.12  4.8 years $81,430 
 Exercisable-period ending September 30, 2016  16,609,564  $0.12  4.8 years $81,430
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions
 9 Months Ended
Sep. 30, 2016
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS
9.RELATED PARTY TRANSACTIONS

 

a) Dr. Ronald Moomaw (“Moomaw”), a director of the Company, is the sole owner of the MED-CURE Companies. The Company received a majority of its revenue for the nine months ended September 30, 2016 from the MED-Cure Companies.

 

In connection with the management of the Med-Cure Companies, Moomaw was issued a warrant for the purchase of 5,000,000 shares of the Company?s common stock valued @ $465,000, the fair value at the time of issuance, April 17, 2015.  

 

Moomaw also received consulting fees of $114,800 and $39,600 for the nine months ended September 30, 2016 and 2015, respectively, as part of his management compensation.  

 

b) The Company advanced operating funds on a short-term basis to the MED-CURE Companies and received payments during the nine months ended September 30, 2016 and the year ended December 31, 2015. As of September 30, 2016 and December 31, 2015, the MED-CURE Companies owe the Company $677,560 and $100,000, respectively.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Common Stock
 9 Months Ended
Sep. 30, 2016
Common Stock [Abstract]  
COMMON STOCK
10. COMMON STOCK

 

On June 15, 2016, the Company issued 100,000 shares of the Company’s common stock to LKB Partners LLC in connection with a service agreement with the Company. The fair value of the common stock issued was $8,000, of which $6,000 was expensed during the nine months ended September 30, 2016.

 

On June 15, 2016, the Company issued 200,000 shares of the Company’s common stock to Harcharan Narang M.D. in connection with a service agreement with the Company. The fair value of the common stock issued was $16,000, all of which was expensed during the nine months ended September 30, 2016.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Major Customers
 9 Months Ended
Sep. 30, 2016
Major Customers [Abstract]  
MAJOR CUSTOMERS
11. MAJOR CUSTOMERS

 

87% of the revenues for the nine months ended September 30, 2016, was received from companies owned 100% by Dr. Ronald Moomaw, a director of the Company.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2016
Commitments and Contingencies [Abstract]  
COMMITMENTS AND CONTINGENCIES
12. COMMITMENTS AND CONTINGENCIES

 

Consulting Agreements

 

a) During 2015 and 2014, Lifestyle entered into various consulting agreements with third parties in connection with business advisory services. For the nine months ended September 30, 2016 and 2015, consulting services amounted to $190,579 and $111,187, respectively.

 

b) On July 1, 2012, Lifestyle entered into an employment agreement with Christopher Smith("Smith"), the Company's Chief Executive Officer. The term of the agreement is for five years. Effective August 1, 2015, the monthly salary for Smith was increased to $12,500. Smith will also receive a performance bonus based on a percentage of the Company's net operating profit before income taxes. For the nine months ended September 30, 2016, and 2015, payroll-officer amounted to $112,500 and $60,000, respectively.
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangibles (Tables)
 9 Months Ended
Sep. 30, 2016
Intangibles [Abstract]  
Components of intangible assets

License Agreements
     
 Balance January 1, 2015 $88,893 
      
 Amortization for the year ended December 31, 2015  (5,555)
      
 Balance December 31, 2015  83,338 
      
 Amortization for the nine months ended September 30, 2016  (4,164)
      
 Balance September 30, 2016 $79,174
Schedule of estimated amortization expense for intangible assets

 

 Year Ending Amortization 
 December 31, Expense 
 2016  1,391 
 2017  5,555 
 2018  5,555 
 2019  5,555 
 2020  5,555
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2016
Property and Equipment [Abstract]  
Schedule of property and equipment

 

   September 30,  December 31, 
   2016  2015 
 Equipment $432,152  $157,152 
 Accumulated depreciation  78,939   22,856 
   $353,213  $134,296
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2016
Debt [Abstract]  
Summary of short-term debt

 

   September 30,  December 31, 
   2016  2015 
 Short-term Debt      
        
 Secured promissory note, interest @ 12% per annum, due June 30, 2016 $150,000  $150,000 
          
 Unsecured promissory note, interest @ 10%, due June 30, 2016  75,000   75,000 
          
 Convertible promissory note, interest @ 10% per annum, due April 2, 2016  100,000   100,000 
          
 Convertible promissory note, interest @ 12% per annum, due April 28, 2017 and June 8, 2017 (2)  358,465   431,465 
          
 Convertible promissory note, interest @ 12% per annum, due December 17, 2016  100,000   100,000 
          
 Convertible promissory note, interest @ 10% per annum, due September 23, 2016  50,000   12,600 
          
 Unsecured promissory note, interest @ 10% per annum, due November 1, 2016  25,000   25,000 
          
 Secured promissory note, interest @ 6% per annum due April 1, 2017 (4)  275,000   - 
          
 Convertible promissory note, interest @ 12% per annum, due June 13, 2017 (3)  250,000   - 
          
 Convertible promissory note, interest @ 12% per annum, due August 24, 2018 (5)  42,512   - 
    1,425,977   894,065 
 Less: Current portion  1,383,465   894,065 
 Long-term debt $42,512  $- 

 

(1)On February 18, 2016, the Company executed an unsecured promissory note with Gail Keats and received $30,000. The promissory note is interest-free and is payable on or before August 15, 2016. The Company repaid the note in full in July 2016.

 

(2)On May 16, 2016, the Company amended its loan agreements with Roy Meadows (“Meadows”). The Company agreed to pay Meadows a renewal fee of $28,000 and $27,956 on its two outstanding loans with Meadows and extend the maturity dates of the loans to April 28, 2017 and June 8, 2017, respectively. The new outstanding balances of the loans including interest and the renewal fees amounted to $308,000 and $307,520, respectively.

 

The Company also agreed to amend the conversion price of the loans into the Company’s common stock to $0.10 per share. At any time, the holder of the notes, at his option, shall have the right to convert the outstanding principal balance or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company. The fair value of the common stock at the date of issuance of the advance was $0.13, which created a Beneficial Conversion Feature of $409,766, the Beneficial Conversion Feature was recorded as a debt discount over the life of the notes. The debt discount as of September 30, 2016 was $257,055.

 

The Company performed an analysis under ASC 470-50 criteria to determine if the note extension agreement falls under debt modification or debt extinguishment criteria. The Company revalued the warrants issued and agreed the additional consideration, extended maturity dates and interest to the extended agreement. The Company deems that based on the analysis performed, debt extinguishment does exist and recorded loss on debt extinguishment in the amount of $61,697.

 

(3)On June 13, 2016, the Company issued a convertible promissory note to Meadows and received proceeds of $250,000.The promissory note bears interest @ 12% per annum and matures one year from the date of issuance. On October 13, 2016, the promissory note was amended increasing the principal amount to $500,000 under the same terms and conditions of the promissory note for funds received in a second loan advance. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.15 per share.

 

(4)On April 1, 2016, the Company issued a secured promissory note to Emile Fares, M,D, (the “Payee”) and promised to the Payee $275,000 in exchange for all the medical equipment owned by RMC Totalcare Medical PA.. The secured promissory note bears interest @ 6% per annum and matures one year from the date issuance. A payment of $75,000 is due October 1, 2016 and the balance due on the maturity date. The note is secured by all collections received by LifeStyle Texas Medical Management LLC pursuant to a Management Agreement with RMC Totoalcare Medical PA.

 

(5)On August 24, 2016, the Company issued a convertible note to Daniel Hagen and received proceeds of $50,000. The promissory note bears interest @ 10% per annum and matures on August 24, 2018. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.06 per share. The fair value of the common stock at the date of issuance of the advance was $0.07, which created a Beneficial Conversion Feature of $8,333, the Beneficial Conversion Feature was recorded as a debt discount over the life of the note. The debt discount as of September 30, 2016 was $7,488.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounts Payable and Accrued Expenses (Tables)
 9 Months Ended
Sep. 30, 2016
Accounts Payable and Accrued Expenses [Abstract]  
Schedule of accounts payable and accrued expenses

   September 30,  December 31, 
   2016  2015 
 Interest $118,477  $68,807 
 Salaries - Officer  -   1,125 
 Professional fees  98,221   64,306 
 Consulting  33,515   48,000 
 Other  16,302   15,639 
   $266,515  $197,877
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants (Tables)
 9 Months Ended
Sep. 30, 2016
Warrants [Abstract]  
Schedule of changes in warrants outstanding

 

      Exercise  Remaining Intrinsic 
   Shares  Price  Life Value 
 Outstanding, January 1, 2016  8,000,000  $0.13  4.6    
 Granted  8,609,564   0.08  5.0    
 Expired/Cancelled  -   -       
 Exercised  -   -       
 Outstanding-period ending September 30, 2016  16,609,564  $0.12  4.8 years $81,430 
 Exercisable-period ending September 30, 2016  16,609,564  $0.12  4.8 years $81,430
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangibles (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Components of intangible assets    
Intangible assets, beginning balance $ 83,338  
Amortization 4,164 $ 18,534
Intangible assets, ending balance 80,562  
MPL License Agreement [Member]    
Components of intangible assets    
Intangible assets, beginning balance 83,338 $ 88,893
Intangible assets, ending balance $ 79,174  
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangibles (Details 1)
Sep. 30, 2016
USD ($)
Estimated amortization expense for intangible assets  
2016 $ 1,391
2017 5,555
2018 5,555
2019 5,555
2020 $ 5,555
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Intangibles (Details Textual) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Intangible (Textual)    
Fee of gross receipts of licensee, Percentage 6.00%  
Term of license agreement 20 years  
Amortization period of license agreement 19 years 6 months  
Amortization expense $ 4,164 $ 18,534
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Loan Receivable-Related Party (Details) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Loan Receivable-Related Party (Textual)      
Advances to related party $ 842,560   $ 180,000
Repayments of related party debt 265,000 $ 80,000 80,000
Loan receivable-related party $ 677,560   $ 100,000
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment (Details) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Property and Equipment [Abstract]    
Equipment $ 432,152 $ 157,152
Accumulated depreciation 78,939 22,856
Property and equipment,net $ 353,213 $ 134,296
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Property and Equipment (Details Textual) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Property and Equipment (Textual)    
Depreciation expense $ 56,083 $ 17,632
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt (Details) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Short-term Debt [Line Items]    
Short-term debt $ 1,425,977 $ 894,065
Less: Current portion 1,383,465 894,065
Short-term debt, Net 42,512
Long-term debt 42,512
Secured promissory note, interest @ 12% per annum, due June 30, 2016    
Short-term Debt [Line Items]    
Short-term debt 150,000 150,000
Unsecured promissory note, interest @ 10%, due June 30, 2016    
Short-term Debt [Line Items]    
Short-term debt 75,000 75,000
Convertible promissory note, interest @ 10% per annum, due April 2, 2016    
Short-term Debt [Line Items]    
Short-term debt 100,000 100,000
Convertible promissory note, interest @ 12% per annum, due April 28, 2017 and June 8, 2017 (2)    
Short-term Debt [Line Items]    
Short-term debt [1] 358,465 431,465
Convertible promissory note, interest @ 12% per annum, due December 17, 2016    
Short-term Debt [Line Items]    
Short-term debt 100,000 100,000
Convertible promissory note, interest @ 10% per annum, due September 23, 2016    
Short-term Debt [Line Items]    
Short-term debt 50,000 12,600
Unsecured promissory note, interest @ 10% per annum, due November 1, 2016    
Short-term Debt [Line Items]    
Short-term debt 25,000 25,000
Secured promissory note, interest @ 6% per annum due April 1, 2017 (4)    
Short-term Debt [Line Items]    
Short-term debt [2] 275,000
Convertible promissory note, interest @ 12% per annum, due June 13, 2017 (3)    
Short-term Debt [Line Items]    
Short-term debt [3] 250,000
Convertible promissory note, interest @ 12% per annum, due August 24, 2018 (5)    
Short-term Debt [Line Items]    
Short-term debt [4] $ 42,512
[1] On May 16, 2016, the Company amended its loan agreements with Roy Meadows ("Meadows"). The Company agreed to pay Meadows a renewal fee of $28,000 and $27,956 on its two outstanding loans with Meadows and extend the maturity dates of the loans to April 28, 2017 and June 8, 2017, respectively. The new outstanding balances of the loans including interest and the renewal fees amounted to $308,000 and $307,520, respectively. The Company also agreed to amend the conversion price of the loans into the Company's common stock to $0.10 per share. At any time, the holder of the notes, at his option, shall have the right to convert the outstanding principal balance or any portion of the principal amount hereof, and any accrued interest into shares of common stock of the Company. The fair value of the common stock at the date of issuance of the advance was $0.13, which created a Beneficial Conversion Feature of $409,766, the Beneficial Conversion Feature was recorded as a debt discount over the life of the notes. The debt discount as of September 30, 2016 was $257,055. The Company performed an analysis under ASC 470-50 criteria to determine if the note extension agreement falls under debt modification or debt extinguishment criteria. The Company revalued the warrants issued and agreed the additional consideration, extended maturity dates and interest to the extended agreement. The Company deems that based on the analysis performed, debt extinguishment does exist and recorded loss on debt extinguishment in the amount of $61,697.
[2] On April 1, 2016, the Company issued a secured promissory note to Emile Fares, M,D, (the "Payee") and promised to the Payee $275,000 in exchange for all the medical equipment owned by RMC Totalcare Medical PA.. The secured promissory note bears interest @ 6% per annum and matures one year from the date issuance. A payment of $75,000 is due October 1, 2016 and the balance due on the maturity date. The note is secured by all collections received by LifeStyle Texas Medical Management LLC pursuant to a Management Agreement with RMC Totoalcare Medical PA.
[3] On June 13, 2016, the Company issued a convertible promissory note to Meadows and received proceeds of $250,000.The promissory note bears interest @ 12% per annum and matures one year from the date of issuance. On October 13, 2016, the promissory note was amended increasing the principal amount to $500,000 under the same terms and conditions of the promissory note for funds received in a second loan advance. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion of the principal hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.15 per share.
[4] On August 24, 2016, the Company issued a convertible note to Daniel Hagen and received proceeds of $50,000. The promissory note bears interest @ 10% per annum and matures on August 24, 2018. At any time, the holder of the note, at his sole option, shall have the right to convert the outstanding principal amount of this note, or any portion hereof, and any accrued interest into shares of common stock of the Company, at a conversion price of $0.06 per share. The fair value of the common stock at the date of issuance of the advance was $0.07, which created a Beneficial Conversion Feature of $8,333, the Beneficial Conversion Feature was recorded as a debt discount over the life of the note. The debt discount as of September 30, 2016 was $7,488.
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Debt (Details Textual)
 3 Months Ended 9 Months Ended
Aug. 24, 2016
USD ($)
$ / shares
Jun. 13, 2016
USD ($)
$ / shares
May 16, 2016
USD ($)
$ / shares
Apr. 01, 2016
USD ($)
Feb. 18, 2016
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
OutstandingLoan
Sep. 30, 2015
USD ($)
Oct. 13, 2016
USD ($)
Debt (Textual)                    
Beneficial conversion feature               $ 426,121 $ 40,000  
Debt discount               254,095 625,335  
Loss on extinguishment of debt           61,697  
Interest expense               $ 107,484 $ 64,532  
Secured promissory note, interest @ 12% per annum, due June 30, 2016                    
Debt (Textual)                    
Debt instrument interest rate           12.00%   12.00%    
Debt instrument, maturity date               Jun. 30, 2016    
Unsecured promissory note, interest @ 10%, due June 30, 2016                    
Debt (Textual)                    
Debt instrument interest rate           10.00%   10.00%    
Debt instrument, maturity date               Jun. 30, 2016    
Convertible promissory note, interest @ 10% per annum, due April 2, 2016                    
Debt (Textual)                    
Debt instrument interest rate           10.00%   10.00%    
Debt instrument, maturity date               Apr. 02, 2016    
Convertible promissory note, interest @ 12% per annum, due April 28, 2017                    
Debt (Textual)                    
Debt instrument interest rate           12.00%   12.00%    
Debt instrument, maturity date               Apr. 28, 2017    
Number of outstanding loans | OutstandingLoan               2    
Convertible promissory note, interest @ 12% per annum, due April 28, 2017 | Roy Meadows [Member]                    
Debt (Textual)                    
Conversion price | $ / shares     $ 0.10              
Fair value of common stock advance per share | $ / shares     $ 0.13              
Beneficial conversion feature     $ 409,766              
Debt discount               $ 257,055    
Convertible promissory note, interest @ 12% per annum, due April 28, 2017 | Outstanding Loan One [Member] | Roy Meadows [Member]                    
Debt (Textual)                    
Debt instrument, maturity date     Apr. 28, 2017              
Renewal fee amount     $ 28,000              
Outstanding loans including interest and renewal fees     308,000              
Convertible promissory note, interest @ 12% per annum, due April 28, 2017 | Outstanding Loan Two [Member] | Roy Meadows [Member]                    
Debt (Textual)                    
Renewal fee amount     $ 27,956              
Convertible promissory note, interest @ 12% per annum, due August 24, 2018                    
Debt (Textual)                    
Debt instrument interest rate           12.00%   12.00%    
Debt instrument, maturity date               Aug. 24, 2018    
Convertible promissory note, interest @ 12% per annum, due August 24, 2018 | Daniel Hagen [Member]                    
Debt (Textual)                    
Debt instrument interest rate 10.00%                  
Debt instrument, maturity date Aug. 24, 2018                  
Conversion price | $ / shares $ 0.06                  
Fair value of common stock advance per share | $ / shares $ 0.07                  
Beneficial conversion feature $ 8,333                  
Debt discount               $ 7,488    
Proceeds from convertible promissory note $ 50,000                  
Convertible promissory note, interest @ 12% per annum, due December 17, 2016                    
Debt (Textual)                    
Debt instrument interest rate           12.00%   12.00%    
Debt instrument, maturity date               Dec. 17, 2016    
Convertible promissory note, interest @ 10% per annum, due September 23, 2016                    
Debt (Textual)                    
Debt instrument interest rate           10.00%   10.00%    
Debt instrument, maturity date               Sep. 23, 2016    
Unsecured promissory note, interest @ 10% per annum, due November 1, 2016                    
Debt (Textual)                    
Debt instrument interest rate           10.00%   10.00%    
Debt instrument, maturity date               Nov. 01, 2016    
Unsecured promissory note, interest @ 10% per annum, due August 15, 2016                    
Debt (Textual)                    
Proceeds from unsecured promissory note with Gail Keats         $ 30,000          
Secured promissory note, interest @ 6% per anum due April 1, 2017                    
Debt (Textual)                    
Debt instrument interest rate       6.00%            
Debt instrument, maturity date       Oct. 01, 2016            
Secured promissory note       $ 275,000            
Payments of debt       $ 75,000            
Convertible promissory note, interest @ 12% per annum, due June 13, 2017                    
Debt (Textual)                    
Debt instrument interest rate           12.00%   12.00%    
Debt instrument, maturity date               Jun. 13, 2017    
Convertible promissory note, interest @ 12% per annum, due June 13, 2017 | Roy Meadows [Member]                    
Debt (Textual)                    
Debt instrument interest rate   12.00%                
Conversion price | $ / shares   $ 0.15                
Proceeds from convertible promissory note   $ 250,000                
Convertible promissory note, interest @ 12% per annum, due June 8, 2017 [Member]                    
Debt (Textual)                    
Debt instrument interest rate           12.00%   12.00%    
Debt instrument, maturity date               Jun. 08, 2017    
Convertible promissory note, interest @ 12% per annum, due June 8, 2017 [Member] | Outstanding Loan Two [Member] | Roy Meadows [Member]                    
Debt (Textual)                    
Debt instrument, maturity date     Jun. 08, 2017              
Outstanding loans including interest and renewal fees     $ 307,520              
Subsequent Event [Member] | Convertible promissory note, interest @ 12% per annum, due June 13, 2017 | Roy Meadows [Member]                    
Debt (Textual)                    
Debt principal amount                   $ 500,000
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Accounts Payable and Accrued Expenses (Details) - USD ($)
Sep. 30, 2016
Dec. 31, 2015
Accounts Payable and Accrued Expenses [Abstract]    
Interest $ 118,477 $ 68,807
Salaries - Officer 1,125
Professional fees 98,221 64,306
Consulting 33,515 48,000
Other 16,302 15,639
Accounts payable and Accrued expenses, Total $ 266,515 $ 197,877
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basic and Diluted Earnings per Share (Details)
 9 Months Ended
Sep. 30, 2016
shares
Basic and Diluted Earnings Per Share (Textual)  
Anti-dilutive shares 11,622,521
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants (Details) - Warrants [Member]
 9 Months Ended
Sep. 30, 2016
USD ($)
$ / shares
shares
Shares  
Outstanding, Beginning Balance | shares 8,000,000
Granted | shares 8,609,564
Expired/Cancelled | shares
Exercised | shares
Outstanding, Ending Balance | shares 16,609,564
Exercisable | shares 16,609,564
Exercise Price  
Outstanding, Beginning Balance | $ / shares $ 0.13
Granted | $ / shares 0.08
Expired/Cancelled | $ / shares
Exercised | $ / shares
Outstanding, Ending Balance | $ / shares 0.12
Exercisable | $ / shares $ 0.12
Remaining Life  
Outstanding, Beginning Balance 4 years 7 months 6 days
Granted 5 years
Exercisable 4 years 9 months 18 days
Outstanding, Ending Balance 4 years 9 months 18 days
Intrinsic Value  
Outstanding, Ending Balance | $ $ 81,430
Exercisable | $ $ 81,430
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants (Details Textual) - Warrant [Member]
 9 Months Ended
May 16, 2016
USD ($)
$ / shares
shares
Apr. 01, 2016
USD ($)
$ / shares
shares
Sep. 30, 2016
USD ($)
Consultants
$ / shares
shares
Jun. 13, 2016
$ / shares
shares
Warrants (Textual)        
Fair value of warrants     $ 708,910  
Dividend yield     0.00%  
Maximum [Member]        
Warrants (Textual)        
Expected term     7 years  
Risk free interest rate     1.56%  
Volatility     424.00%  
Minimum [Member]        
Warrants (Textual)        
Expected term     5 years  
Risk free interest rate     1.39%  
Volatility     202.00%  
Roy Meadows [Member]        
Warrants (Textual)        
Issuance of warrant to purchase common stock | shares 1,059,564      
Exercise price | $ / shares $ 0.025      
Bonus warrant | shares 500,000      
Renewal warrant | shares 559,564      
Fair value of warrants $ 112,555      
Roy Meadows [Member] | Financing [Member]        
Warrants (Textual)        
Issuance of warrant to purchase common stock | shares       250,000
Exercise price | $ / shares       $ 0.025
Fair value of warrants     $ 17,500  
Interest expense     5,104  
Harcharan Narang M.D [Member]        
Warrants (Textual)        
Issuance of warrant to purchase common stock | shares   800,000    
Exercise price | $ / shares   $ 0.20    
Fair value of warrants   $ 80,000    
Interest expense     39,890  
Prepaid expenses     $ 40,110  
Consultants [Member]        
Warrants (Textual)        
Issuance of warrant to purchase common stock | shares     6,500,000  
Fair value of warrants     $ 500,000  
Interest expense     $ 7,499  
Number of consultants | Consultants     4  
Prepaid expenses     $ 492,501  
Consultants [Member] | Maximum [Member]        
Warrants (Textual)        
Exercise price | $ / shares     $ 0.08  
Consultants [Member] | Minimum [Member]        
Warrants (Textual)        
Exercise price | $ / shares     $ 0.07  
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions (Details) - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Related Party Transactions (Textual)      
Companies owe amount $ 677,560   $ 100,000
Med Cure Companies [Member]      
Related Party Transactions (Textual)      
Issuance of warrant to purchase common stock 5,000,000    
Fair value of warrant $ 465,000    
Moomaw received consulting fees $ 114,800 $ 39,600  
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Common Stock (Details) - USD ($)
 1 Months Ended 9 Months Ended
Jun. 15, 2016
Sep. 30, 2016
LKB Partners LLC [Member]    
Common Stock (Textual)    
Common stock shares issued 100,000  
Fair value of common stock issued   $ 8,000
Fair value of common stock issued expense   6,000
Harcharan Narang M.D [Member]    
Common Stock (Textual)    
Common stock shares issued 200,000  
Fair value of common stock issued   $ 16,000
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Major Customers (Details)
 9 Months Ended
Sep. 30, 2016
Dr. Ronald Moomaw (Director) [Member]  
Major Customers (Textual)  
Concentration Risk, Percentage 100.00%
Sales Revenue, Net [Member]  
Major Customers (Textual)  
Concentration Risk, Percentage 87.00%
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Details Textual) - USD ($)
 9 Months Ended
Jul. 01, 2012
Sep. 30, 2016
Sep. 30, 2015
Employment Agreement [Member]      
Commitments and Contingencies (Textual)      
Term of employment agreement 5 years    
Amount of compensation as per payroll - officer   $ 112,500 $ 60,000
Monthly salaries $ 12,500    
Consulting Agreements [Member] | Related Party Consulting Services [Member]      
Commitments and Contingencies (Textual)      
Consulting fees   $ 190,579 $ 111,187
EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 49 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 91 176 1 true 31 0 false 6 false false R1.htm 001 - Document - Document and Entity Information Sheet http://lifestylemedicalnetwork.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - Consolidated Balance Sheets Sheet http://lifestylemedicalnetwork.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://lifestylemedicalnetwork.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://lifestylemedicalnetwork.com/role/ConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://lifestylemedicalnetwork.com/role/ConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - Description of Business and Summary of Significant Accounting Policies Sheet http://lifestylemedicalnetwork.com/role/DescriptionOfBusinessAndSummaryOfSignificantAccountingPolicies Description of Business and Summary of Significant Accounting Policies Notes 6 false false R7.htm 007 - Disclosure - Intangibles Sheet http://lifestylemedicalnetwork.com/role/Intangibles Intangibles Notes 7 false false R8.htm 008 - Disclosure - Loan Receivable-Related Party Sheet http://lifestylemedicalnetwork.com/role/LoanReceivableRelatedParty Loan Receivable-Related Party Notes 8 false false R9.htm 009 - Disclosure - Property and Equipment Sheet http://lifestylemedicalnetwork.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 010 - Disclosure - Debt Sheet http://lifestylemedicalnetwork.com/role/Debt Debt Notes 10 false false R11.htm 011 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://lifestylemedicalnetwork.com/role/Accountspayableandaccruedexpenses Accounts Payable and Accrued Expenses Notes 11 false false R12.htm 012 - Disclosure - Basic and Diluted Earnings per Share Sheet http://lifestylemedicalnetwork.com/role/BasicAndDilutedEarningsPerShare Basic and Diluted Earnings per Share Notes 12 false false R13.htm 013 - Disclosure - Warrants Sheet http://lifestylemedicalnetwork.com/role/Warrants Warrants Notes 13 false false R14.htm 014 - Disclosure - Related Party Transactions Sheet http://lifestylemedicalnetwork.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 015 - Disclosure - Common Stock Sheet http://lifestylemedicalnetwork.com/role/CommonStock Common Stock Notes 15 false false R16.htm 016 - Disclosure - Major Customers Sheet http://lifestylemedicalnetwork.com/role/MajorCustomers Major Customers Notes 16 false false R17.htm 017 - Disclosure - Commitments and Contingencies Sheet http://lifestylemedicalnetwork.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 018 - Disclosure - Intangibles (Tables) Sheet http://lifestylemedicalnetwork.com/role/IntangiblesTables Intangibles (Tables) Tables http://lifestylemedicalnetwork.com/role/Intangibles 18 false false R19.htm 019 - Disclosure - Property and Equipment (Tables) Sheet http://lifestylemedicalnetwork.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://lifestylemedicalnetwork.com/role/PropertyAndEquipment 19 false false R20.htm 020 - Disclosure - Debt (Tables) Sheet http://lifestylemedicalnetwork.com/role/DebtTables Debt (Tables) Tables http://lifestylemedicalnetwork.com/role/Debt 20 false false R21.htm 021 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://lifestylemedicalnetwork.com/role/Accountspayableandaccruedexpensestables Accounts Payable and Accrued Expenses (Tables) Tables http://lifestylemedicalnetwork.com/role/Accountspayableandaccruedexpenses 21 false false R22.htm 022 - Disclosure - Warrants (Tables) Sheet http://lifestylemedicalnetwork.com/role/WarrantsTables Warrants (Tables) Tables http://lifestylemedicalnetwork.com/role/Warrants 22 false false R23.htm 023 - Disclosure - Intangibles (Details) Sheet http://lifestylemedicalnetwork.com/role/Intangiblesdetails Intangibles (Details) Details http://lifestylemedicalnetwork.com/role/IntangiblesTables 23 false false R24.htm 024 - Disclosure - Intangibles (Details 1) Sheet http://lifestylemedicalnetwork.com/role/IntangiblesDetails1 Intangibles (Details 1) Details http://lifestylemedicalnetwork.com/role/IntangiblesTables 24 false false R25.htm 025 - Disclosure - Intangibles (Details Textual) Sheet http://lifestylemedicalnetwork.com/role/IntangiblesDetailsTextual Intangibles (Details Textual) Details http://lifestylemedicalnetwork.com/role/IntangiblesTables 25 false false R26.htm 026 - Disclosure - Loan Receivable-Related Party (Details) Sheet http://lifestylemedicalnetwork.com/role/LoanReceivableRelatedPartyDetails Loan Receivable-Related Party (Details) Details http://lifestylemedicalnetwork.com/role/LoanReceivableRelatedParty 26 false false R27.htm 027 - Disclosure - Property and Equipment (Details) Sheet http://lifestylemedicalnetwork.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://lifestylemedicalnetwork.com/role/PropertyAndEquipmentTables 27 false false R28.htm 028 - Disclosure - Property and Equipment (Details Textual) Sheet http://lifestylemedicalnetwork.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) Details http://lifestylemedicalnetwork.com/role/PropertyAndEquipmentTables 28 false false R29.htm 029 - Disclosure - Debt (Details) Sheet http://lifestylemedicalnetwork.com/role/DebtDetails Debt (Details) Details http://lifestylemedicalnetwork.com/role/DebtTables 29 false false R30.htm 030 - Disclosure - Debt (Details Textual) Sheet http://lifestylemedicalnetwork.com/role/DebtDetailsTextual Debt (Details Textual) Details http://lifestylemedicalnetwork.com/role/DebtTables 30 false false R31.htm 031 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://lifestylemedicalnetwork.com/role/Accountspayableandaccruedexpensesdetails Accounts Payable and Accrued Expenses (Details) Details http://lifestylemedicalnetwork.com/role/Accountspayableandaccruedexpensestables 31 false false R32.htm 032 - Disclosure - Basic and Diluted Earnings per Share (Details) Sheet http://lifestylemedicalnetwork.com/role/BasicandDilutedEarningsperShareDetails Basic and Diluted Earnings per Share (Details) Details http://lifestylemedicalnetwork.com/role/BasicAndDilutedEarningsPerShare 32 false false R33.htm 033 - Disclosure - Warrants (Details) Sheet http://lifestylemedicalnetwork.com/role/WarrantsDetails Warrants (Details) Details http://lifestylemedicalnetwork.com/role/WarrantsTables 33 false false R34.htm 034 - Disclosure - Warrants (Details Textual) Sheet http://lifestylemedicalnetwork.com/role/WarrantsDetailsTextual Warrants (Details Textual) Details http://lifestylemedicalnetwork.com/role/WarrantsTables 34 false false R35.htm 035 - Disclosure - Related Party Transactions (Details) Sheet http://lifestylemedicalnetwork.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://lifestylemedicalnetwork.com/role/RelatedPartyTransactions 35 false false R36.htm 036 - Disclosure - Common Stock (Details) Sheet http://lifestylemedicalnetwork.com/role/CommonStockDetails Common Stock (Details) Details http://lifestylemedicalnetwork.com/role/CommonStock 36 false false R37.htm 037 - Disclosure - Major Customers (Details) Sheet http://lifestylemedicalnetwork.com/role/MajorCustomersDetails Major Customers (Details) Details http://lifestylemedicalnetwork.com/role/MajorCustomers 37 false false R38.htm 038 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://lifestylemedicalnetwork.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://lifestylemedicalnetwork.com/role/CommitmentsAndContingencies 38 false false All Reports Book All Reports lmnk-20160930.xml lmnk-20160930.xsd lmnk-20160930_cal.xml lmnk-20160930_def.xml lmnk-20160930_lab.xml lmnk-20160930_pre.xml true true ZIP 54 0001213900-16-018813-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-16-018813-xbrl.zip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end